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ADDICTION AS DISEASE  
 
Teneille R. Brown, JD* 
Abstract 
 
The opioid addiction epidemic is the most overwhelming public health 
crisis our country has faced. It is now creating a legal crisis, as the its 
poisonous fruits spill over into the criminal, tort, and family courts. The 
epidemic costs the U.S. economy about $500 billion every year, and the 
pressure is crippling our legal systems. This Article is an attempt to relieve 
some of that pressure, by advocating for a comprehensive public health 
campaign based upon a new model of addiction. Research shows that the 
prevalent “moral choice” model of addiction has facilitated stigma and 
discouraged treatment, by viewing affected individuals as blameworthy, 
different in kind, and hopeless. Even when programs are accessible, which 
they often are not, individuals will not seek treatment because they fear 
adopting the label of “addict.” In this Article, I affirmatively reject the 
moral choice model, identifying it as an obstacle to mitigating the opioid 
epidemic. In its place, I offer a model of addiction that more closely tracks 
its complex disease etiology, while humanizing people with addiction, 
removing stigma, and encouraging treatment. I refer to this model as the 
“integrated disease model,” or IDM, as it explains addiction as a neuro-
genetic phenomenon, but does not locate addiction entirely in the brain. 
Rather, it places addiction on equal footing with other chronic diseases, 
such as lung cancer or diabetes, each of which has significant genetic, 
behavioral, and environmental causes. This Article will explain 1) how the 
moral choice model leads to no treatment and poor treatment, 2) how the 
law has furthered stigma through the criminalization of addiction, 3) and 
why we need to fund a comprehensive public health campaign based upon 
findings from neuro-genetics and public health. The IDM emphasizes the 
biological continuum of genetic risk factors to which we are all susceptible, 
the neurological networks that are impaired once the addiction has taken 
hold, and finally, the incredible power of evidence-based treatments. 
Explaining addiction in this way –as a treatable, complex disease—has been 
shown to reduce stigma and encourage treatment.  
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A.  The Problem of Addiction Stigma 
 
 Stigma is a powerful and multidimensional social force. It can be 
based on visible markings like skin color or leprosy, or it can be based on 
invisible characteristics such as being widowed or mentally ill. Essentially, 
stigma is defined as labeling differences in others, then using those 
differences to reduce someone from “whole and usual” to “tainted and 
discounted.”1 Stigma must be understood with reference to a power 
structure, as it reproduces inequities among under-privileged groups.2 Like 
stereotyping, the process of stigmatization relies on sticky 
overgeneralizations, which in turn are used to justify social exclusion, 
prejudice, and discrimination.3 Stigma manifests in three distinct ways. It 
first develops between members of a society through gossip and social 
sanctions, then may become manifest in legal and social institutions such as 
housing and employment, and eventually is internalized by those 
stigmatized, leading to shame and reduced feelings of self-worth.4  
 Drug addiction is extraordinarily stigmatized. A comprehensive 
study by the World Health Organization found that drug addiction ranked at 
the top of a list eighteen stigmatized social problems.5 Among mental 
illnesses, which as a group are quite stigmatized, drug addiction ranks as the 
most stigmatized disorder, with lay people rating “addicts” as more 
dangerous, less predictable, and more to blame for their disorders than 
                                                
1 Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know; 
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 3 (2013) 
2Laramie Smith, et al., Substance Use Stigma: reliability and validity of a theory-based scale for 
substance-using populations 162 DRUG ALCOHOL DEPENDENCE 34, 36 
3 National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against 
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, at p.4; (2016) 
Washington, DC: The National Academies Press. doi: 10.17226/23442; available for download at 
www.NAP.edu.   
4 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 275 
(2017); National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against 
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, at p.4; (2016) 
Washington, DC: The National Academies Press. doi: 10.17226/23442; available for download at 
www.NAP.edu;  
5 Robin Room, et al, “Cross-Cultural Views on Stigma Valuation Parity and Societal Attitudes 
towards Disability,” in T.B. Üstün and S. Chatterji, eds., Disability and Culture: Universalism and 
Diversity (Seattle: Hogrefe & Huber, 2001): 247–291; as cited in Daniel Buchman, et al., The 
Epidemic as Stigma: The Bioethics of Opioids, 45 J. Law Med. And Ethics, 607, 607(2017).  
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people with depression or schizophrenia.6 With blame comes moral 
judgment.7  
 Because the word “addict” carries with it such negative 
connotations, and conflates the disorder with the individual, the preferred 
convention now is to refer to addicts as people with substance use disorder, 
or SUD. Studies have shown that the way we talk about addiction matters, 
and can exacerbate stigma.8 However, as this article is exploring the very 
underpinnings of these negative connotations and the social response to the 
label of “addict”, I will sometimes employ the non-clinical and stigmatized 
terminology.   
 The predominant narrative of addiction holds that it is caused by a 
weak character and immoral choices. Media portrayals rely on this model, 
with ubiquitous stories of individual addicts who made bad decisions, broke 
the law, and never obtained sobriety. This “moral choice” model has 
facilitated stigma, by treating affected individuals as blameworthy, different 
in kind, and hopeless. Coincidentally, these same attributes are frequently 
used to dehumanize individuals, and to justify social distance, harsh 
punishment and legal discrimination. Stigma associated with the moral 
choice model has discouraged many people from getting treatment, as they 
resist adopting the label of the “addict” even when their disorder is 
advanced. Quite literally, stigma kills.9 
 As addiction manifests in socially undesirable behavior, judgment 
toward people with SUD is understandably complicated. People with SUD 
may deceive and manipulate to obtain drugs or hide use. Erecting healthy 
boundaries with someone with SUD is not enacting stigma. This may be 
necessary self-protection. We can, however, discourage the unhealthy and 
antisocial behavior, without shaming the individual by helping these 
individuals seek clinical treatment, and understanding that their decisions 
are highly constrained by a powerful disease. Frankly, we must, re-
humanize addiction by treating addiction like any other complex, and 
                                                
6 M.C. Angermeyer and Sandra Dietrich, Public Beliefs about and Attitudes Towards People with 
Mental Illness: a review of population studies, 113 Acta Psychiatr. Scand. 163, 170 (2006) 
7 M.C. Angermeyer and Sandra Dietrich, Public Beliefs about and Attitudes Towards People with 
Mental Illness: a review of population studies, 113 Acta Psychiatr. Scand. 163, 170 (2006):“[Our 
research showed] that people addicted to drugs were viewed as significantly more responsible for 
their disorder compared to people with mental illness or those in a wheelchair…blame [led to 
perceptions] that they were most able to overcome it.” 
8 For example, when physicians received a vignette that described the patient as a “substance abuser,” 
as opposed to “someone with substance abuse disorder,” they were more likely to blame the 
individual for his problem, and think he should be punished for not adhering to court-ordered 
treatment. See, Harvard Mental Health Letter, Harvard In-brief, April 2010, available online at 
http://www.health.harvard/edu/newsletter_article/addiction-terminology-affects-clinicisn-attitudes-
towards-patients.  
9 Sarah Wakeman & Josiah Rich, Barriers to Medications for Addiction Treatment: How Stigma 
Kills, 53 SUBSTANCE USE AND MISUSE 330, 330 (2018). 
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chronic disease. Once addiction is properly conceived of as a disease, we 
can then make sure that people with SUD have access to treatment, so they 
can stop the cycle of antisocial behavior. Just as people with bipolar 
disorder or depression may at times seem “selfish” or difficult to handle, we 
should not use their untreated behavior as a justification for denying them 
treatment. 
 In this Article, I affirmatively reject the moral choice model. In its 
place, I offer a model of addiction that more closely tracks its disease 
etiology, while humanizing people with addiction, removing stigma, and 
encouraging treatment. I refer to this model as the integrated disease model, 
or IDM, as it explains addiction as a neuro-genetic phenomenon, but does 
not locate addiction entirely in the brain. Rather, it places addiction on 
equal footing with other complex and chronic diseases, such as lung cancer, 
or diabetes, which also have significant genetic, behavioral, and 
environmental causes.10 Employing the IDM, I advocate for a massive, new, 
federal public health campaign that uses neuro-genetic findings and stories 
of recovery to demonstrate that people with addiction are not blameworthy, 
not different in kind, and not hopeless.  
 By emphasizing that addiction is a disease, and thus prioritizing 
prevention and treatment of affected individuals first and foremost, we can 
hopefully reduce the unfair stigma that hinders recovery and leads to 
antisocial behaviors. After clinical care is prioritized, we can then work on 
social policies that promote inclusion, such as criminal justice reform and 
fair housing and employment practices. But a key premise of this Article is 
that we ought not “jump the gun” to focus on social determinants of health, 
when we have not even adopted a model of addiction that prioritizes the 
primary determinants of health. 
 This Article will thus proceed in four brief parts. In the first part, I 
will provide evidence for the existence of stigma toward people with SUD, 
and explain how it leads to no treatment and poor treatment. In the second 
                                                
10 Lung cancer and diabetes can be caused by personal choices and behavior, such as smoking 
cigarettes, eating too much sugar, or using intravenous needles. So too can addiction be caused in part 
by voluntary choices to consume drugs. There are also genetic and biological vulnerabilities to lung 
cancer and diabetes, just as there are with addiction, that can exacerbate risk and make conditions 
worse. Given that Type 2 diabetes is sometimes caused by eating too many carbohydrates and sugars, 
it remains stigmatized, even with its clear adoption as a medical disease. The IDM will not remove all 
stigma. See generally, Jessica Browne, et al., ‘I call it the blame and shame disease’: a qualitative 
study about perceptions of social stigma surrounding type 2 diabetes, 18 BMJ Open e003384 
(2013)Without delving too far into the sociology of health, there are of course difficulties 
distinguishing between an illness (where a person experiences symptoms) a disease (where someone 
calls for professional help) and a sickness (where the person adopts the social role of patient). 
However, the disease model is used as a heuristic to explain a medically-oriented model, that 
encourages reflection on the biological and environmental causes of disease. See, Anna-
Henrikje Seidlein and Sabine Salloch, Illness and disease: an empirical-ethical viewpoint, 20 BMC 
MEDICAL ETHICS 5, 5 (2019) 
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part, I will explain the law’s role in furthering stigma through the 
criminalization of addiction, and our ineffective efforts to reduce stigma 
through statutes like the Americans with Disabilities Act. In the third 
section, I will explain competing models of addiction, providing evidence 
for a disease model based on neuro-genetic causes and effects. In the fourth 
section, I conclude with my recommendation for a new public health 
campaign, based upon the IDM and the neuro-genetic risks of addiction. As 
compared to previous models of addiction, which have focused attention 
either exclusively on choice or the brain, this model incorporates aspects of 
both to treat addiction like other chronic diseases. Employing the IDM, I 
advocate for a massive, new, federal public health campaign that uses 
neuro-genetic findings and stories of recovery to demonstrate that people 
with addiction are not blameworthy, not different in kind, and not hopeless.  
 
B.  Why This Matters: The Opioid Crisis is a Public Health 
Emergency 
 
 At the same time as physicians were recognizing rampant under-
treatment of pain, pharmaceutical companies in the 1990s began 
aggressively marketing new opioid medications that they claimed were 
unlikely to be abused.11 This proved to be fatally, fraudulently, wrong.12 
Consumption of oxycodone increased by a whopping 500% from 1999 to 
2011, and opioid-related overdoses almost quadrupled.13 The alarming 
increase in opioid use has led to the “worst drug overdose epidemic in [US] 
history,” according to the Centers for Disease Control.14 
 Overdose deaths from opioids have led to an absolute decline in life 
expectancy in the United States, and it is the number one cause of 
accidental death.15 In 2016, the overdose death rate from synthetic opioids 
doubled from the last year, likely driven by an influx of potent, non-
                                                
11 Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health 
Tragedy, 99 AM. J. PUBLIC HEALTH 221, 223 (2009) 
 “A consistent feature in [Purdue Pharmaceutical’s] promotion and marketing of OxyContin was a 
systematic effort to minimize the risk of addiction in the use of opioids for the treatment of chronic 
non–cancer-related pain.” 
12 Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health 
Tragedy, 99 AM. J. PUBLIC HEALTH 221, 223 (2009) 
 “A consistent feature in [Purdue Pharmaceutical’s] promotion and marketing of OxyContin was a 
systematic effort to minimize the risk of addiction in the use of opioids for the treatment of chronic 
non–cancer-related pain.” 
13 Andrew Kolodny, et al., The Prescription Opioid and Heroin Crisis: A Public Health Approach to 
an Epidemic of Addiction,  36 ANNUAL REVIEW OF PUBLIC HEALTH 559, 559 (2015). 
14 Andrew Kolodny, et al., The Prescription Opioid and Heroin Crisis: A Public Health Approach to 
an Epidemic of Addiction,  36 ANNUAL REVIEW OF PUBLIC HEALTH 559, 559 (2015). 
15 Peter Muenning, et al., America’s Declining Well-Being, Health, and Life Expectancy: Not Just a 
White Problem, 108 AM. J. PUBLIC HEALTH 1626, 1626 (2018) 
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prescription fentanyl from China.16 More than a hundred people continue to 
die from the epidemic every day17. This has led the Department of Health 
and Human Services and the President of the United States to declare our 
modern addiction crisis a “public health emergency.”18 
 The opioid crisis has exposed a devastating reality: with the right 
combination of environmental stress19 and genetic vulnerability20, any of us 
could become addicted to drugs. Any of us could start taking OxyContin for 
kidney stones or a sports injury, and end up living on the streets after our 
family has kicked us out. Any of us could die of a heroin or fentanyl 
overdose. A big part of what separates those who become addicted from 
those who do not is something entirely outside of our control: our genes.  
 Many who have been touched by the opioid crisis now appreciate 
that anyone can become addicted, regardless of race or socio-economic 
status. However, stigma is still felt by people with opioid use disorder 
(OUD), and disproportionately so for those from lower social classes. 
Indeed, social class is a better predictor of adverse outcomes from addiction 
then the patterns or volume of drug use itself.21 While people who 
experience childhood trauma are at an increased risk of developing SUD22, 
addiction is still addiction when it manifests. And it is still largely viewed 
as a disease of the morally bankrupt or the weak-willed. We see this in the 
                                                
16 See, Centers for Disease Control Newsroom, U.S. drug overdose deaths continue to rise; 
increase fueled by synthetic opioids, March 29, 2018, available online at 
https://www.cdc.gov/media/releases/2018/p0329-drug-overdose-deaths.html. (“Across demographic 
categories, the largest increase in opioid overdose death rates was in males between the ages of 25-
44.”); see also, Colleen Barry, Fentanyl and the Evolving Opioid Epidemic: what strategies should 
policy makers consider? 69 PSYCHIAT. SERV. 100, 100 (2018) (encouraging a public health messaging 
campaign that educates on the risks of fentanyl). 
17 Health and Human Services, What is the U.S. Opioid Epidemic?, 
HTTPS://WWW.HHS.GOV/OPIOIDS/ABOUT-THE-EPIDEMIC/INDEX.HTML, UPDATED JAN. 2019 
18 “On October 26, 2017, President Trump announced that his Administration was declaring the 
opioid crisis a national Public Health Emergency under federal law, effective immediately. ‘I am 
directing all executive agencies to use every appropriate emergency authority to fight the opioid 
crisis,’ the President said.” See, The White House, The Opioid Crisis, available online 
https://www.whitehouse.gov/opioids/ 
19 Shelly Wiechelt & Shulamith Lala A. Straussner, Introduction to the Special Issue: Examining the 
Relationship Between Trauma and Addiction 15 J. SOCIAL WORK PRACTICE IN THE ADDICTIONS 1, 1 
(2015) (“Furthermore, it is empirically well established that there is a link between trauma-related 
disorders and sub- stance use disorders.”) See also, Annett Lotzin, et al., Profiles of Childhood 
Trauma in Patients with Alcohol Dependence and Their Associations with Addiction-Related 
Problems, 40 ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH 543, 543 (2016)“The high 
occurrence of childhood trauma in individuals with alcohol dependence is well-recognized.”  
20 Nora D. Volkow and A. Thomas McLellan, Opioid Abuse in Chronic Pain — Misconceptions 
and Mitigation Strategies 374 NEW ENGL. J. MED. 1253, 1257 (2016) 
21 Robin Room, Stigma, Social Inequality and Alcohol and Drug Use, 24 DRUG AND ALCOHOL 
REVIEW 143, 143 (2005) 
22 Shelly Wiechelt & Shulamith Lala A. Straussner, Introduction to the Special Issue: Examining 
the Relationship Between Trauma and Addiction 15 J. SOCIAL WORK PRACTICE IN THE ADDICTIONS 1, 
1 (2015) 
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way that people think addiction should be treated, which is often through 
peer-counseling, jail time, and cold-turkey abstinence, rather than through a 
health care clinic.23 
 
I. EVIDENCE OF ADDICTION STIGMA 
 
 It is perhaps no surprise that people with SUD are extensively 
stigmatized. However, the extent of the stigma is a bit astounding. 
Widespread stigma presents at the social, structural, and personal levels. In 
this section I will analyze the evidence for each. Given how frequently 
people hold stigmatized views of addicts, and how this leads to massive 
under-treatment, it is disconcerting that fewer than ten experimental studies 
exist on SUD stigma24. Despite the clear evidence we have of the existence 
of stigma from observational studies and surveys, more empirical research 
needs to be done on how best to mitigate it.  
 
a. Social Stigma 
 
 Americans report wanting considerable social distance from people 
with SUD. People with SUD are rated as having little social value, and 
therefore it is considered acceptable not to help them, and to exclude them 
from social spaces.25 For example, 75% of Americans are unwilling to have 
someone with drug dependence move next door to them.26 Nearly 60% of 
Americans would be unwilling to make friends with someone with “drug 
dependence,” and nearly 73% would be unwilling to even spend one 
evening socializing with an addict.27 Let that sink in. Given this extreme 
desire for social distance, it is no wonder that 90% of respondents say they 
are unwilling to have someone with drug dependence marry into their 
family. Seventy-eight percent say they are unwilling to have someone with 
                                                
23 See, Barbara Andraka-Christou, America Needs the Treat Act: Expanding Access to Effective 
Medication for Treating Addiction, 26 HEALTH MATRIX 309, 335 (2016).National Academies of 
Science, Ending Discrimination Against People with Mental and Substance Use Disorders: The 
Evidence for Stigma Change, available for download at http://nap.edu/23442, at p. 1 
24 Patrick Corrigan & Katherine Nieweglowski, Stigma and the public health agenda for the opioid 
crisis in America, 59 INTL. J. OF DRUG POLICY 44, 44
 
(2018) 
25 Patrick Corrigan, et al., The Public Stigma of Mental Illness and Drug Addiction: Findings from a 
Stratified Random Sample, 9 J. SOC. WORK 139, 139 (2009); see also Kumiko Yoshioko, et al., 
Associations between Beliefs about the Causes of Mental Disorders and Stigmatizing Attitudes: 
Results of a Mental Health Literacy and Stigma Survey of the Japanese Public, 45 INT. J. MENTAL 
HEALTH 183, 183 (2016); Shuntaro Ando et al, Review of mental-health-related stigma in Japan,  67 
PSYCH CLIN. NEUROSCI. 471, 471 (2013) 
26 Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know; 
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 9 (2013) 
27 Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know; 
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 9 (2013) 
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drug dependence work closely with them on their job.28 These levels of 
stigmatizing attitudes are quite a bit higher than for people with depression 
or schizophrenia.29   
 The little research on stigma that is specific to OUD reveals that the 
stigma persists in the face of our recent crisis. Many thought that stigma 
might be lessened. Unlike heroin or cocaine, which are illegal, OUD could 
have begun with a valid prescription from a doctor, even if the pills were 
later diverted to someone without a prescription. Some thought this might 
reduce the moral judgment against people with OUD, given its ambiguous 
legal status.30 It was also thought that because the people affected by OUD 
were more likely to be white, wealthy, and have insurance, compared to 
those impacted by the previous addiction crises (such as the cocaine 
epidemic of the 1980s and 90s), people may have less stigmatizing attitudes 
toward them.  
 So far, this has not turned out to be the case. The prevalence of 
OUD is not decreasing many forms of stigma. Respondents with personal 
experience with someone with OUD were more likely to say that 1) people 
with OUD are to blame for their disorder, 2) some people lack the self-
discipline to use pain medications responsibly, and 3) and employers and 
landlords should be allowed to deny employment or housing to people with 
OUD.31 Fewer people are unwilling to have someone with OUD work 
closely with them (59%) or marry into the family (66%), compared to 
previous studies of drug addiction generally.32 However, the desire for 
social distance remains quite high in the general population, and in some 
cases is slightly higher for people who have personal experience with 
someone with OUD. Greater exposure to people with SUD is not going to 
be the silver-bullet to reducing stigma. This might be due to the 
manipulative behavior that these friends have experienced. They are not 
discriminating based upon ignorance of addiction; they are discriminating 
based upon perceived behavior. This must be addressed at the systemic 
level, by creating effective treatments and improving access to them, and by 
removing the stigma associated with being someone with SUD.   
 Most Americans believe that people with SUD are dangerous and 
                                                
28 Colleen Barry, et al, Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views 
about Drug Addiction and Mental Illness, 65 Psych. Serv. 1271 (2014) 
29 Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know; 
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 9 (2013) 
30 Kennedy-Hendricks, et al, 68 Psychiatric Serv.462 (2017) 
31 Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid  
Use Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies, 
68 PSYCHIATRIC SERV. 462 (2017) 
32 Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid Use 
Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies,  
68 PSYCHIATRIC SERV. 462, 466 (2017)  
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unpredictable.33 Despite evidence that people with SUD are more likely to 
injure themselves, many Americans believe that persons with alcohol or 
drug addiction are more likely to be violent toward others.34 This is likely 
due to the depiction of people with drug addiction in the mass media and 
popular culture.  
 Our knowledge about persons with addictions is shaped through the 
“visible, marginalized street populations of persons with addictions, or 
through stereotypes of persons with addictions as portrayed in movies.”35 
Unfortunately, people with SUD are represented in film in stereotypical 
ways that do not reflect their diverse lives.36 Society has become inured to 
viewing portrayals of untreated people with SUD as “disheveled, often 
homeless, and potentially dangerous.”37 We need to depict people with 
SUD in more mainstream, and diverse, ways.38  
 Individuals with substance use disorders elicit great social distance 
across all stakeholders. The public, family members, and even health care 
providers hold stigmatizing views of addicts. Most these groups think that 
people with SUD are not trustworthy, tend to be aggressive, and tend to be 
criminal.39 Even drug users themselves stigmatize the route of drug 
administration, with intravenous drug users being considered dirtier and 
worse off than those who abuse oral pain medications.40  
 The stigma that health care providers feel toward people with SUD 
is well-documented. When physicians hold beliefs about the causes of 
addiction that are stigmatizing and moralizing, this creates significant 
barriers to people with SUD obtaining adequate treatment.41 Not only are 
                                                
33 M.C. Angermeyer and Sandra Dietrich, Public Beliefs about and Attitudes Towards People with 
Mental Illness: a review of population studies, 113 ACTA PSYCHIATR. SCAND. 163, 169 (2006) 
34 Bernice Pescosolido, et al., “A Disease Like Any Other,” A decade of change in public reactions to 
schizophrenia, depression, and alcohol dependence, 167 AM. J. PSYCH. 1321, 1321 (2010); see also 
CL Barry, et al, After Newtown—public opinion on gun policy and mental illness, 368 NEW ENGLAND 
J. MED. 1077 (2013);  
35 Anne Marie Lavack, Using social marketing to de-stigmatize addictions: A review, 15 ADDICTION 
IN RESEARCH AND THEORY, 479, *3 (2007) 
36 Anne Marie Lavack, Using social marketing to de-stigmatize addictions: A review, 15 
ADDICTION IN RESEARCH AND THEORY, 479, *3 (2007) 
37 Colleen Barry, et al., Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views 
About Drug Addiction and Mental Illness, 65 PSYCHIATRIC SERVICES 1269, 1272 (2014) 
38 Patrick Corrigan, Karina J. Powell, and Patrick J. Michaels, The Effects of News Stories on the 
Stigma of Mental Illness, 201 JOURNAL OF NERVOUS AND MENTAL DISEASE 179, 181 (2013) 
39 Leonieke C van Boekel,  et al., Comparing stigmatising attitudes towards people with substance 
use disorders between the general public, GPs, mental health and addiction specialists and clients, 61 
Int. J of Social Psychiatry, 539, 544 (2014). 
40 Peter Flom, et al., Stigmatized drug use, sexual partner concurrency, and other sex risk network 
and behavior characteristics of 18 to 24-year-old youth in a high-risk neighborhood, 28 SEXUALLY 
TRANSMITTED DISEASES, 598 (2001) 
41 Katharine Press, et al., What Patients with Addiction Disorders Need from their Primary Care 
Physicians: a qualitative study, 32 SUBSTANCE ABUSE 349-355 (2016); Moira Ray, et al., Patient and 
Provider Comfort Discussing Substance Abuse, 45 FAMILY MEDICINE 109 (2013); see also Leonieke 
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patients less likely to seek care because they feel judged or ashamed, these 
physicians might ignore addiction risk factors due to personal discomfort 
with the disorder. Additionally, patients will not be completely honest with 
their providers when they perceive these moralized and judgmental 
beliefs.42 This will lead to under-treatment or inappropriate treatments. 
 
b. Structural Stigma 
  
 Structural stigma is manifest by public and private actors, including 
judges, prosecutors, legislators, social services, banks, insurance companies, 
restaurants, schools, and clubs. Stigma at the structural level appears as an 
endorsement of discrimination, which contributes to public and self-
stigma.43 Structural stigma places unfair limits on someone’s exercising 
their civil rights due to the label of addict, rather than being based on any 
observable behavior. Examples include “discriminatory legislation that 
places restrictions on jury service, voting, holding political office, and 
parental custody rights”44 as well as discriminatory hiring or admissions 
policies based on stereotypes.”45 It also includes the lack of parity between 
insurance coverage for addiction treatment and other forms of medical 
treatment.46 It remains too soon to tell whether federal parity is helping to 
increase treatment and reduce stigma,47 but there continue to be many 
                                                                                                                       
C van Boekel,  et al., Comparing stigmatising attitudes towards people with substance use disorders 
between the general public, GPs, mental health and addiction specialists and clients, 61 Int. J of 
Social Psychiatry, 539, 544 (2014). 
42 Lily Frank and Saskia Nagel, Addiction and Moralization: the role of the underlying model of 
addiction, 10 NEUROETHICS 129, 133 (2017)  
43 National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against 
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, Summary at 
p.4-5; (2016) Washington, DC: The National Academies Press. doi: 10.17226/23442; available for 
download at www.NAP.edu.   
44National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against 
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, Research 
Stragegies, at p.105; (2016) Washington, DC: The National Academies Press. doi: 10.17226/23442; 
available for download at www.NAP.edu 
45 National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against 
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, Summary at 
p.4-5; (2016) Washington, DC: The National Academies Press. doi: 10.17226/23442; available for 
download at www.NAP.edu.   
46 “One reason for this lack of parity between medical care and addiction services may be stigma; if 
addiction disorders are perceived as the fault of the addicted and not worthy of treatment, then 
regulators and the public will be less likely to press for equal coverage.” See, Valarie K. Blake, 
Engaging Health Insurers in the War on Prescription Painkillers, 11 HARV. L. & POL'Y REV. 485, 
501 (2017) 
47 Colleen Barry, Howard Goldman, Haiden Huskamp, Federal Parity In The Evolving Mental 
Health And Addiction Care Landscape, 35 HEALTH AFFAIRS, 1009, 1015 (2016) (“[T]he incentives 
for health plans to avoid adverse selection do not go away in the presence of federal parity, since 
there will still be variation across plans with respect to the generosity of the mental health and sub- 
stance use disorder benefits offered. The next five years will be critical to gaining a detailed picture 
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aspects of the delivery of addiction treatment that are less accessible and 
inferior to regular medical care.48 
 Stigma has far-reaching effects, and impacts how people think about 
addressing SUD as a social problem. For example, 43% of respondents say 
they are opposed to individuals with drug addiction receiving equivalent 
insurance benefits, with 49% opposed to increased government spending on 
treatment and a whopping 76% opposed to increased government spending 
on housing.49 These percentages are much higher than those for mental 
illness generally, and have been tied to stigma.  
 The fact that people with SUD are overrepresented in the criminal 
justice system, is both a consequence and a source of structural stigma.50 In 
a large study of attitudes toward people with OUD, higher levels of stigma 
were associated with greater support for punitive policies.51 These punitive 
policies included greater criminalization, and permission to discriminate in 
housing and employment. Those who held greater stigmatized views of 
SUD also had lower support for public health-oriented policies like 
demanding insurance parity between physical and mental health services, 
and improving treatment access and harm reduction strategies.52  
 
c.  Self-Stigma 
 
 Self-stigma includes negative views that stigmatized individuals 
believe others think about them. It also refers to negative thoughts and 
shame that emerge from identification with a stigmatized group.53 At the 
personal level, most, but not all, individuals with SUD feel considerable 
shame for their disorder. This is probably due in part to a feeling that they 
are failing in exercising agency, and in “letting ourselves down we typically 
let down others who rely on us.”54  Despite this internally focused shame, 
                                                                                                                       
of the extent to which parity is improving the health and well-being of people diagnosed with a 
mental health or substance use disorder, and to better assessing what new policies are needed to build 
on the Wellstone-Domenici law’s achievements.”) 
48 Corey Davis, et al., Action, Not Rhetoric, Needed to Reverse the Opioid Overdose Epidemic, 45 J. 
LAW, MED. & ETHICS 20, 21 (2017) (describing lack of access to evidence-based treatment, and 
under-enforcement of the Mental Health Parity and Addiction Equity Act.) 
49 Colleen Barry, et al, Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views 
about Drug Addiction and Mental Illness, 65 PSYCH. SERV. 1271 (2014) 
50 National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against 
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, at p.4; (2016) 
Washington, DC: The National Academies Press. doi: 10.17226/23442; available for download at 
www.NAP.edu.   
51C Dackis and C O”Brien, Neurobiology of Addiction: treatment and public policy ramifications, 8 
NATURE NEUROSCIENCE 1431,1431 (2008) 
52 Kennedy-Hendricks, et al, 68 Psychiatric Serv.462 (2017) 
53 van Brakel et al., 2006 
54 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276 
(2017); 
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there is certainly a component that is also caused by the external, social 
stigma that people with SUD experience.55 Perceptions of public stigma 
feed into normative self-concepts, so that people with SUD tend to have 
reduced self-esteem56. The common representation of addicts as unreliable 
or untrustworthy, for example, can make affected individuals feel excluded 
from the public sphere, and lead them to see themselves as deserving of this 
shunning treatment.57 They then might withdraw from society, and stop 
seeking employment and participating in their communities in healthy 
ways. And most importantly, they will then be motivated to continue to 
consume drugs or alcohol to reduce the negative feelings that stem from 
their shame. This is what some researchers have dubbed the “looping 
effect,” as the label of “addict” can feed back into negative behavior, that 
then reinforces the negative judgments around the label.58  
 
It is possible to separate shame from blame. Many of us experience 
shame for things that are not socially blameworthy or immoral (such as 
having a physical disability). This is particularly acute if the stigmatized 
condition makes others worried that we are contagious or they experience 
disgust at the sight of us. But the truth is that when personal shame is 
experienced as part of social stigma for a behavior that is viewed rightly or 
wrongly as immoral, then the emotion of shame immediately stimulates 
feelings of moral failure.59  
 
 Research on self-stigma in OUD has demonstrated that the higher 
the self-stigma, the higher the rates of depression for affected individuals.60 
Additionally, people who reported recent injection drug use have been 
found to have significantly higher mean scores on validated measures of 
                                                
55 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 275 
(2017); 
56 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276 
(2017); 
57 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276 
(2017); 
 
58 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 278 
(2017); 
 
59 Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276 
(2017); 
 
60Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification, 
12 J ADDICT MED. 19–23 (2018); “General Self-Stigma Subscale scores were associated positively 
and significantly with PHQ-2 depression (r = 0.36, p < .001) as were Treatment Stigma Subscale 
scores (r = 0.14, p = 0.004).” 
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self-stigma.61 And individuals who reported having accessed detoxification 
care had higher rates of self-stigma than those who had not, which the 
researchers believed was due to a feeling that their treatments had failed.62 
Interestingly, this same study found that the self-stigma ratings were higher 
for wealthier people with higher levels of education.63 Perhaps within this 
group they feel like they have more social value to lose, and are therefore 
more afraid of adopting the label of addict, or acknowledging their 
substance use disorder.   
 
 People with SUD exhibit stigmatized views toward people with 
more “severe” forms of the disorder. For example, one study found that 
people abusing pain meds “held stigmatising attitudes towards those who 
used heroin, with employment, education and appearance listed as reasons 
why people who used codeine were more ‘respectable’”.64  Another 
qualitative study of people in treatment for over-the-counter codeine 
dependence in Australia found there were perceptions that MAT was for 
“drug users”, and was for “other people”, namely those using intravenous 
heroin.65 Even among people with drug addiction, there is a hierarchy of 
shame and othering of those more severely affected. 
 
2. Stigma Leads to No Treatment and Poor Treatment 
 
 Public health messaging from the last several decades has focused 
on instilling fear in children—painting a terrible picture of addicts as dirty, 
pathetic, dishonest, and homeless. While these campaigns may have worked 
in the past, they are now backfiring. The popular construction of the addict 
as a dangerous, unpredictable criminal has led to massive under-treatment.  
While more than 2.3 million people in the U.S. have an opioid use disorder, 
less than 40% receive evidence-based treatment.66 The reason in part, lies 
                                                
61 Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification, 
12 J ADDICT MED. 19, *4 (2018). 
62 Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification, 
12 J ADDICT MED. 19, *6 (2018). 
63 Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification, 
12 J ADDICT MED. 19, *6 (2018). 
64Sasha Cooper, et al., Perceived stigma and social support in treatment for pharmaceutical opioid 
dependence, 37 DRUG & ALCOHOL REVIEW 262, 263 (2018) 
 
65 Suzanne Nielsen, et al., Pharmaceutical opioid analgesic and heroin dependence: How do 
treatment-seeking clients differ in Australia?, 30 DRUG AND ALCOHOL REVIEW 291, 297 (2011) 
(“There may be societal elements at play, such as the reported perception that opioid substitution 
treatments—of which the majority of participants in this study were recruited from—are primarily for 
‘drug users’, specifically heroin users.”) 
66 Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to 
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S230 (2018) 
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with stigma. Stigma is routinely among the most common reasons people 
with SUD give for not initiating treatment or maintaining treatments that 
allow for sustained abstinence.67 Stigma has been labeled “the most 
important obstacle to the provision of mental health care.”68 As such, the 
U.S. Substance Abuse and Mental Health Services Administration 
(“SAMHSA”) prioritizes reducing stigma, as it is an essential barrier to 
treatment and public health goals.69 Stigma discourages affected individual 
from seeking treatment, as they do not want to adopt the label of an 
“addict.”70 Stigma also increases shame which might perpetuate substance 
use,71 discourages their health care providers from treating them adequately, 
72 and makes insurance coverage less accessible and more expensive.73 
Even if someone can overcome the many hurdles to receiving adequate 
addiction treatment, stigma is still associated with negative mental and 
physical health consequences.74  
 Not only does stigma provide a reason for denying the disorder and 
not accessing treatment, but it also impacts the quality of the treatment that 
people with SUD receive. A 2015 public opinion survey found that only 
                                                
67 Sara Wallhed Finn, Ann-Sofie Bakshi & Sven Andreasson, Alcohol consumption, dependence, and 
treatment barriers: perceptions among nontreatment seekers with alcohol dependence, 49 
SUBSTANCE USE MISUSE, 762, 762 (2014); Charlotte Probst, et al., Alcohol use disorder severity and 
reported reasons not to seek treatment: a cross-sectional study in European primary care practices, 
10 Substance Abuse Treatment, Prevention, and Policy (2015) (“Of 1,008 patients diagnosed with an 
alcohol use disorder (via general practitioner or patient interview) in the past 12 months, the majority 
(N = 810) did not receive treatment and 251 of those gave a reason for not seeking treatment. The 
most frequent reason was ‘lack of problem awareness’ (55.3 % of those who responded), the second 
most common response was ‘stigma or shame’ (28.6 %), followed by ‘encounter barriers’ (22.8 %) 
and ‘cope alone’ (20.9 %)”). 
68 NORMAN SARTORIUS, FIGHTING STIGMA: THEORY AND PRACTICE, 1 World Psychiatry 26, 27 (2002)  
69 Patrick Corrigan & Katherine Nieweglowski, Stigma and the public health agenda for the opioid 
crisis in America 59 INT. J. DRUG POLICY 44, 44 (2018) 
70 Laramie Smith, et al., Substance Use Stigma: reliability and validity of a theory-based scale for 
substance-using populations 162 DRUG ALCOHOL DEPENDENCE 34, 36; C Erikson, The Science of 
Addiction: From Neurobiology to Treatment, New York, New York, W.W. Norton Press (2007), at p. 
3; Laura Williamson, Destigmatizing Alcohol Dependence: the requirement for ethical (not only 
medical) remedy, 102 AMERICAN J. OF PUBLIC HEALTH e5, e6 (2012) 
71 [cite] 
72 LEONIEKE VAN BOEKEL, ET AL., STIGMA AMONG HEALTH PROFESSIONALS TOWARDS PATIENTS WITH 
SUBSTANCE USE DISORDERS AND ITS CONSEQUENCES FOR HEALTHCARE DELIVERY: SYSTEMATIC REVIEW, 131 
Drug and Alcohol Dependence 23, 23 (2013); MUKHERJEE R,  ET AL, THE STIGMATISATION OF 
PSYCHIATRIC ILLNESS: THE ATTITUDES OF MEDICAL STUDENTS AND DOCTORS IN A LONDON TEACHING 
HOSPITAL, 26 PSYCHIATR BULL 178-181 (2002) (MORE THAN 50% OF CLINICIANS FELT PATIENTS WITH 
SCHIZOPHRENIA, AND DRUG AND ALCOHOL ADDICTION WERE DANGEROUS, UNPREDICTABLE.) 
73 “Historically, insurers have not funded addiction treatment as generously as other costly medical 
services like cardiac care or organ transplant. Addicted patients were sometimes excluded from 
enrollment in insurance or charged very high premiums. Some insurers also opted not to cover 
addiction services, or pushed the costs of these services back onto patients through very high co-
pays.” See, Valarie K. Blake, Engaging Health Insurers in the War on Prescription Painkillers, 11 
HARV. L. & POL'Y REV. 485, 501 (2017) 
74 Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification, 
12 J ADDICT MED. 19–23 (2018) 
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19% of Americans surveyed thought medication assisted treatment 
(MAT)—the gold standard for opioid use disorder treatment —was the best 
way to treat heroin dependence, preferring strategies like Narcotics 
Anonymous that involve being “drug free.”75 At least 2.3 million people in 
the U.S. have OUD, yet over 60% do not receive evidence-based 
treatment.76 Only 4% of licensed MDs are approved to prescribe 
buprenorphine, an effective drug that helps curb cravings for opioids and 
withdrawal symptoms.77 Of over 14,000 drug treatment programs in the US, 
some funded by federal block grants to states, most are not staffed with a 
single licensed medical practitioner.78 If addiction were instead conceived 
of as a medical disease, would we see these abysmal levels of evidence-
based treatment?    
 Take for example, provider’s feelings toward Naloxone. Naloxone is 
a short-acting mu-opioid antagonist that can be injected by emergency 
responders who encounter someone who has recently overdosed. It quickly 
reverses the acute effects of a drug overdose, such as respiratory 
depression.79 Despite its ability to save lives, research suggests that 
providers have generally negative attitudes about its use. The reasons for 
these attitudes include concerns about “promoting or condoning substance 
use,” the unsafe disposal of needles, and their feelings of frustration, 
futility, and powerlessness.80 The latter is likely due to the drug’s ability to 
stop this overdose, while doing nothing to prevent the next one. 
Buprenorphine and methadone are the drugs that helps with that problem, 
but they are also woefully under-prescribed. 
 Unfortunately, some providers and the public view MAT as 
problematic, as you are “substituting one opioid for another.”81 Part of the 
trouble may be with the mixed message behind the label itself, as 
“Medication-Assisted Treatment” communicates that 1) medication is not 
                                                
75 Bertha Madras, The surge of opioid use, addiction, and overdoses: responsibility and response of 
the US health care system. 74 JAMA PSYCHIATRY 441, 441 (2017) 
76 Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification, 
12 J ADDICT MED. 19–23 (2018): (“There are efficacious treatments for opioid use disorder (OUD), 
however according to the National Survey on Drug Use and Health, of the 2.5 million Americans 12 
years and older who misused or were dependent on opioids in 2012, fewer than 1 million received 
treatment with methadone, buprenorphine/ naloxone or naltrexone.”) 
77 Haffajee, et al., 54 Am. J. Prev. Med. S230 (2018) 
78 Bertha Madras, The surge of opioid use, addiction, and overdoses: responsibility and response of 
the US health care system. 74 JAMA PSYCHIATRY 441, 441 (2017) 
79 NANCY HAUG, ET AL., ASSESSMENT OF PROVIDER ATTITUDES TOWARD #NALOXONE ON TWITTER, 37 
Substance Abuse 35, 35 (2016)  
80 NANCY HAUG, ET AL., ASSESSMENT OF PROVIDER ATTITUDES TOWARD #NALOXONE ON TWITTER, 37 
SUBSTANCE ABUSE 35, 35 (2016)  
81 Lloyd I. Sederer and Leslie A. Marino, Ending the Opioid Epidemic by Changing the Culture, 89 
PSYCHIATRIC QUARTERLY 891, 892 (2018) 
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the primary treatment for SUD, 2) another, unnamed treatment is.82 
Consider, the implications for example, of referring to an insulin 
prescription for diabetes as “Medication-Assisted Treatment.” This label of 
course begs the question—is there any other treatment that is not medical?83  
 Opioid agonists such as methadone or buprenorphine, two common 
forms of MAT, are effective at reducing drug relapse, as they can mitigate 
painful withdrawal and cravings that might fuel the addiction cycle.84 They 
do so by releasing a sustained and small dose of opioids. Without MAT, the 
immediate withdrawal symptoms, such as sweating, shaking, and diarrhea, 
may resolve within a few days.85 Other symptoms, however, such as 
dysphoria, insomnia, and anxiety can linger for months, and drive drug use 
to self-medicate the withdrawal.86 These drugs literally save lives. They 
should be prioritized for what they are—effective medical treatments.  
 For individuals with OUD, more than 80% return to drug use if 
treated with only behavioral interventions, like Narcotics-Anonymous or 
psychotherapy.87 In contrast, treatment with adequately dosed MAT leads to 
only 15% of those treated continuing to use illicit opioids. 88 Buprenorphine, 
in particular, “has demonstrated effectiveness in increasing treatment 
retention, reducing opioid use, reducing mortality, and reducing the 
transmission of HIV and hepatitis C,” and it has some cost, efficacy, and 
administering advantages over methadone, especially when combined with 
Naloxone.89 Because buprenorphine can be delivered in non-specialty 
settings sublingually, or via injection or implant, it can be “less stigmatizing 
for patients, better integrated with other medical care, maintained under a 
                                                
82 Sean Robinson and Bryon Adinoff, The Mixed Message Behind ‘Medication-Assisted Treatment’ 
for Substance Use Disorder, 44 AMERICAN J. OF DRUG AND ALCOHOL ABUSE, 147, 148 (2018) 
83 Sean Robinson and Bryon Adinoff, The Mixed Message Behind ‘Medication-Assisted Treatment’ 
for Substance Use Disorder, 44 AMERICAN J. OF DRUG AND ALCOHOL ABUSE, 147, 148 (2018) 
84 Valerie Hewell, Angel Vasquez, & Inna Rivkin, Systemic and individual factors in the 
buprenorphine treatment-seeking process: a qualitative study, 12 SUBSTANCE ABUSE TREATMENT, 
PREVENTION, AND POLICY 1, 4-5 (2017) (As one person with OUD commented: “(Withdrawal) was 
physical, mental, emotional, spiritual. I was a disaster for like…I think I made it…four days, and then 
I went back.” Participants reported withdrawal made it challenging to quit or stay off opioids without 
support. As one participant noted, “So I had to come off of it cold turkey, and it was a terrible, 
terrible experience, so I just went back to heroin.” As such, participants described MAT as being 
helpful in decreasing withdrawal symptoms, which allowed it to be used as a ‘stepping stone’ to 
recovery”) 
85 Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating 
Addiction Vulnerability, 5 F1000 RESEARCH 1748, 1748 (2016) 
86 Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating 
Addiction Vulnerability, 5 F1000 RESEARCH 1748, 1748 (2016) 
87 Sarah E. Wakeman,Using Science to Battle Stigma in Addressing the Opioid Epidemic: Opioid 
Agonist Therapy Saves Lives, 129 AM. J. MED. 455, 455 (2016)  
88 Sarah E. Wakeman,Using Science to Battle Stigma in Addressing the Opioid Epidemic: Opioid 
Agonist Therapy Saves Lives, 129 AM. J. MED. 455, 455 (2016)  
89 Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to 
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S232 (2018) 
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long-term primary care–patient relationship, and available to special 
populations” such as people in prison or on parole.90 Despite its 
demonstrated clinical effectiveness, because buprenorphine contains small 
amounts of opioids, many physicians and the public stigmatize its use, even 
calling into question whether someone treated with physician-prescribed 
buprenorphine can be considered in recovery, or sober.91  
 This is a dangerous perspective. Stigma surrounding MAT, and “the 
belief that people on MAT were still addicts and not in the recovery 
process,” has interfered with participants’ treatment and recovery.92 Why is 
MAT not respected? Because addiction is not seen as a disease. We treat 
lung cancer with chemotherapy toxins and radiation, realizing that these 
dangerous treatments would not be prescribed to someone without cancer. 
We should treat MAT in the same way we treat other treatment options, by 
prescribing it when its clinical benefits outweigh its risks. In many cases, 
when confronted with continued intravenous drug use and risk of overdose, 
the risks are easily justified.  
 Recognizing the barriers to accessing MAT, Congress passed the 
Drug Addiction Treatment Act in 2000 (“DATA 2000”), allowing 
physicians to request a waiver from the Controlled Substances Act 
requirements to treat OUD outside of a federally-regulated Opioid 
Treatment Program (“OTP”).93 Even still, however, fewer than 4% of 
licensed physicians are approved to prescribe buprenorphine.94 It is 
                                                
90 Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to 
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S233 (2018) 
91 One patient in recovery through MAT explained the stigma toward buprenorphine this way: “I hear 
it all the time: ‘you’re not sober’. And it really hurts my feelings because I worked hard…from where 
I was to where I (am) now…I got my own place, I got my disability, I got everything on track. And all 
she said was, ‘you’re still not sober.’” Valerie Hewell, Angel Vasquez, & Inna Rivkin, Systemic and 
individual factors in the buprenorphine treatment-seeking process: a qualitative study, 12 SUBSTANCE 
ABUSE TREATMENT, PREVENTION, AND POLICY 1, 4-5 (2017) see also, Barbara Andraka-Christou, 
America Needs the Treat Act: Expanding Access to Effective Medication for Treating Addiction, 26 
HEALTH MATRIX 309, 339–40 (2016) (“The War on Drugs contributes to the underuse of 
buprenorphine in two ways: by stigmatizing drug-dependent individuals and by causing them to hide 
their illness (rather than seeking treatment) out of fear of punishment for drug possession.”) 
92 Valerie Hewell, Angel Vasquez, & Inna Rivkin, Systemic and individual factors in the 
buprenorphine treatment-seeking process: a qualitative study, 12 SUBSTANCE ABUSE TREATMENT, 
PREVENTION, AND POLICY 1, 4-5 (2017)  
93 The Drug Addiction Treatment Act, was passed as part of the Children’s Health Act, codified at 21 
U.S.C.A. § 823 (West 2019) 
94 “Surprisingly, utilization of buprenorphine is very low in the U.S., partly due to restrictions placed 
on prescribers under the Drug Addiction Treatment Act (DATA) of 2000. In 2013, Senator Markey 
introduced the Recovery Enhancement for Addiction Treatment Act (TREAT Act) in the Senate, 
which would loosen DATA's patient limit restrictions and expand prescribing ability to nurse 
practitioners and physician assistants. Even though the bill was strongly supported by the American 
Medical Association, American Society of Addiction Medicine, and other professional organizations, 
it received scant media or public attention.” See, Barbara Andraka-Christou, America Needs the Treat 
Act: Expanding Access to Effective Medication for Treating Addiction, 26 HEALTH MATRIX 309, 317 
(2016) 
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estimated that only half of the physicians with waivers actually prescribe 
buprenorphine, and most of those prescribe far below their capacity.95 
Almost half of our counties in the U.S.A. lack a buprenorphine-waivered 
physician, and there is a significant gap between treatment need and 
capacity. This is despite its “high potential” to treat affected individuals, 
due to “its approval for use in non-specialty outpatient settings, 
effectiveness at promoting abstinence, and cost effectiveness.”96 While it 
can be hard to frame this concept for physicians, and may be under-
reported, “many physicians explicitly cite [stigma toward patients with 
SUD] as a barrier.”97  
 
 It is hard to imagine another disease for which there exists such a 
skimpy infrastructure for treatment. Visualize the public outcry, if nearly 
half of our counties did not have a chemotherapy or dialysis clinic, and over 
60% of individuals with cancer did not get evidence-based treatment. Yet 
this is where we are with SUD. And it is precisely because it is seen as a 
moral failing rather than as a medical disease. 
   
II. LEGAL RESPONSE TO STIGMA 
 
A.  Criminalization Fosters Stigma 
 
 To answer, “how did we get here?” we must look not just to the 
media depictions of addicts, but to the over-criminalization of addiction. 
Stigma permits criminalization, but it also is exacerbated by it. The policy 
feedback literature suggests that “enactment of public policies can lead to 
changes in public perceptions of the worthiness of the population targeted 
by the policy and shift political power by creating new constituencies”98 
Not only are policies impacted by social stigma, as politicians will rarely 
expend the capital to protect heavily stigmatized groups, but therapeutic and 
compassionate policies can reduce stigma. Criminalizing drug possession 
does the opposite.  
 
 Recent research demonstrates that the extent to which people 
stigmatize drug addiction predicts their support for punitive policies. For 
example, when asked whether respondents supported arresting and 
                                                
95 Lloyd I. Sederer and Leslie A. Marino, Ending the Opioid Epidemic by Changing the Culture, 89 
PSYCHIATRIC QUARTERLY 891, 892 (2018) 
96 Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to 
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230 (2018) 
97 Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to 
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S233 (2018) 
98 McGinty, et al., 69 PSYCHIATR. SERV. 136 (2017) 
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prosecuting people who “doctor shop” to obtain multiple opioid 
prescriptions, roughly 17% of the variance in support for this policy could 
be explained by ratings of addiction stigma.99 When researchers asked 
whether respondents supported requiring Medicaid enrollees, suspected of 
“problematic” opioid use to use a single prescriber and pharmacy, again 
17% of the variance in support could be explained by stigma.100  Stigma 
was so powerful, it shockingly explained more of the support for punitive 
policies than political affiliation.101 These findings provide powerful 
support for the idea that  “reducing stigma toward individuals with 
prescription OUD might be one way to discourage adoption of punitive 
policies.”102  
 Of course, the criminalization of drug use has led to greater stigma 
for affected individuals as well. The modern “War on Drugs” can be traced 
back to President Richard Nixon, as he declared in 1971 that drug abuse 
was “public enemy number one in the United States.”103 Seizing on this 
perception, Congress began passing “tough on crime” laws that 
criminalized use and possession of drugs, with strict mandatory minimum 
sentences. This continued through the presidencies of Ronald Reagan and 
George H.W. Bush.104  
 
 To build support for his “War,” the Reagan administration sought to 
publicize the threat of crack cocaine. According to Michelle Alexander 
“[a]lmost overnight, the media was saturated with images of black ‘crack 
whores,’ ‘crack dealers,’ and ‘crack babies’—images that seemed to 
confirm the worst racial stereotypes about impoverished inner-city 
residents.”105 In 1986, in response to news coverage that suggested NBA-
recruit Len Bias had overdosed on crack cocaine, Congress adopted the 
1986 Anti-Drug Abuse Act, with little debate and zero hearings.106  The Act 
created a mandatory minimum sentence of five years for possessing five 
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grams of crack with intent to sell, and a minimum of ten years of 
imprisonment for ten grams.107  In 1988, Congress added a five-year 
minimum sentence for simple possession of 5 grams of a mixture of crack 
cocaine.108 It is impossible to speak of the War on Drugs without 
acknowledging how disproportionately it affected people of color. Whereas 
powder cocaine, “associated with a wealthier, whiter class of drug users,” 
required possession of 500 grams to trigger a 5-year prison term, one only 
needed to possess a mere 5 grams of the chemically identical crack cocaine, 
“regarded as a drug of the black urban ghetto,” to trigger the same 
sentence.109 The disparities in sentencing were exquisitely felt by the many 
black communities that were devastated by these harsh penalties. These 
harsh penalties received public support, as they fell on the disempowered 
and “racial other,” which in turn led to greater dehumanization of people of 
color.110 The result, of course, is that in modern America, if you were to 
gaze your eyes on the criminal justice system, you would think that drug 
use and addiction were largely problems for the urban, poor, African-
American community.  Drug addicts were the “other,” and they were 
dangerous. Of course, we know now how biased this snapshot was. It did 
not capture the many white and wealthy Americans who were similarly 
addicted, and it did not fully capture the many people with SUD who were 
neither dangerous nor involved with the criminal justice system.  
 The present opioid addiction crisis reveals just how racialized our 
political responses can be. While it is laudable that legislators are now 
proposing bills that encourage treatment and de-emphasize criminalization, 
it is quite illuminating that these compassionate responses to drug addiction 
have only now been proposed. Perhaps because those affected by OUD are 
more likely to be white, middle-class, older, and living in the suburbs, there 
has been less “othering” of people with OUD. As we might expect, the 
policy and criminal justice responses to OUD do appear to be less punitive 
and more therapeutic. Evidence of this can be found in the Opioid Crisis 
Response Act111, a rare, bipartisan appropriation bill passed by Congress in 
2018, with 99 Senators supporting the bill. The Act provides modest 
funding for research into addiction stigma, and increases housing options 
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for people in recovery.112 Additionally, several federal agencies have 
responded to the opioid crisis with a much more therapeutic and prevention-
based approach.113 However, there remains a dire need for more funding of 
addiction treatment programs and scaling-up of physicians authorized to 
provide MAT.114 
 The Department of Health and Human Services (“HHS”) developed 
a five-point evidence-based strategy in 2017. The five points are: (1) 
increasing addicts’ access to recovery and treatment services; (2) improving 
access to medications that reverse overdoses; (3) improving data collection; 
releasing data more promptly to improve public health response; (4) 
research into pain and addiction, including development of new treatments; 
(5) reducing inappropriate use of opioids by developing better evidence-
based pain treatment.115 This effort is laudable, and does exactly what 
should be done: treating addiction as a disease with devastating public 
health impacts. We certainly saw no such political response to the Crack 
Cocaine epidemic of the 1980s and 1990s, which dehumanized addicts and 
criminalized addiction.   
 Despite the greater efforts to respond to OUD through drug courts116 
and harm reduction programs117, addiction remains heavily criminalized. 
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According to the Federal Bureau of Investigation statistics, in 2016 alone, 
1.57 million drug arrests were made in the United States.118 That is one drug 
arrest every 20 seconds, and represents more than three times the arrests 
made for all violent crimes combined.119 In 2015, the overwhelming 
majority of drug arrests, some 84%, were for possession only, and did not 
include distribution or sales of drugs.120 
 The stigma from incarceration itself can lead to a “why try?” effect, 
where people anticipate stigma and thus see no point in trying to integrate 
back into their communities.121 Conviction can also reduce access to other, 
derivative rights. Having a criminal record tied to drug use can negatively 
impact child custody, voting rights, employment, business loans, licensing, 
student aid, and even public housing.122 While it is not unfair discrimination 
to deny someone custody of their child when they are too dependent on 
opioids to safely take care for their kids, the concern here is that the label of 
“addict” will be doing too much punitive work. Rather than evaluating the 
antisocial behavior of that individual, the label of “addict” will alone 
persuade judges to deny parents custody in ways that might not be in the 
child’s best interests. 
 To be sure, criminalization of addiction would be better justified, 
even given the stigma it creates, if it worked to deter drug use. But based on 
data compiled by the Pew Charitable Trust, imprisonment for drug crimes 
does not reduce drug use, arrests, or overdose deaths.123 By any measure 
that matters, criminalization is not working.124 In 2000, Portugal 
decriminalized drug use and replaced criminal sanctions for those who 
possessed more than a small amount with civil penalties and public health 
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interventions.125 Dr. João Goulão, Portugal’s national drug policy director 
who led the reform said, “the biggest effect has been to allow the stigma of 
drug addiction to fall, to let people speak clearly and to pursue professional 
help without fear.”126 The country has seen a steady decline in the rate of 
new HIV infections as well as overdose deaths.127 
 
B.  Anti-Discrimination Statutes Cannot Effectively Mitigate 
Stigma 
 
 Anti-discrimination statutes prohibit discrimination based on 
someone’s identity or observable characteristics. We therefore have federal 
statutes that prohibit discrimination in housing, employment, and public 
accommodations, based upon specific protected statuses, such as race, 
religion, sex, disability status, or genetic mutations. Another way of 
thinking about this is to require that people judge someone based on the 
content of their actions rather than on their belonging to a particular group, 
which is typically stigmatized. To demonstrate how the anti-discrimination 
statutes work in the context of addiction, let’s analyze the Americans with 
Disabilities Act (“ADA”). 
 Recognizing that people with physical or mental disabilities have 
rights to fully participate in all aspects of society, Congress passed the ADA 
to prohibit discrimination in employment and public accommodation128. It 
was later amended in 2008. The ADA prohibits companies with more than 
fifteen employees from discriminating against a qualified individual on the 
basis of that person's disability, or perceived disability.129 Addiction 
qualifies as a disability, if it physically or mentally impairs the employee 
and limits the employee in a major life activity, such as learning or taking 
care of oneself.130 Once an employer is aware of an ADA-defined disability, 
she must then make “reasonable accommodations to the known physical or 
mental limitations” of the individual.  
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 There are a few ways that the anti-discrimination statutes, such as 
the ADA, will not be enough to protect people with SUD from illegal 
discrimination. In theory, addiction can meet the definition of a disability, 
and therefore must be accommodated so long as the accommodation does 
not create an “undue burden” for the employer.131 But in practice, it is easy 
to fire people with SUD, or exclude them from broad classes of 
employment. First, if you are ever intoxicated at work, your behavior is 
understandably grounds for discipline and is not protected by the ADA.132 
Even so, the employer must apply any disciplinary policies equally to all 
affected employees.133 If your intoxicated behavior embarrassed the 
company, even it occurs outside of your employment, you may be fired and 
it will not violate the ADA.134 There are often pretextual reasons to 
terminate someone with an addiction. If you are covering your addiction 
well, you will not be protected under the ADA, as the employer needs to 
regard you as having a disability.135 It is often difficult to prove that the 
employer knew of your addiction unless you exhibit intoxicated behavior, in 
which case you are also not protected. If you are recently using, you are not 
a qualified person with a disability, and are not protected under the ADA or 
the Family Medical Leave Act, even if none of your behavior led your 
employer to believe you were impaired.136. If you disclose your SUD to 
seek unpaid time off for treatment, employers can then fire you and claim it 
is due to a business necessity reason, even if they had no idea you had any 
problem before you alerted them. If someone is participating in an addiction 
treatment program, has successfully completed a treatment program, or is 
no longer using illegal drugs, they are not excluded as a “qualified 
individual.”137 However, once an employer knows about an employee’s 
SUD, the “business necessity” exception provides for far-reaching 
exclusions to protection, even for people who are now sober.138 Further, if 
you are now sober, some courts will hold that you are no longer 
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experiencing a “disability,” nor are you “regarded as having a disability,” if 
the impairment to your life is not substantial enough.139 This of course 
confuses the status of someone in recovery, as “in this context, [sobriety] is 
not synonymous with a cure; it is a personal process of movement toward a 
meaningful, purposeful, and satisfying life.”140 Despite the stigma attached 
to current or previous SUD, employees are not fully protected from 
discrimination while they are keeping their behavior under control, while 
they are using, while they are exhibiting behavior of intoxication, or when 
they are in recovery.  This leaves very little protection for people with SUD. 
Given the problems with addiction being a heavily stigmatized disorder 
based on biology and behavior, it does not fit neatly within the classes 
protected under various anti-discrimination statutes. As illustrated in its 
ineffective protection under the ADA, it is no wonder that people with SUD 
are regularly discriminated against.  
 In addition to stigma toward SUD, its treatment is stigmatized too. 
The Legal Action Center in New York reports that nursing homes are 
discriminating against potential elderly residents who use MAT (such as 
methadone or buprenorphine), and will deny them residency based upon 
their MAT use. Some organ transplant patients cannot be listed if taking 
MAT,141 and in other instances MAT patients have been forced to taper to 
maintain custody or their jobs.  This sort of discrimination for receiving 
medical treatment, is not protected by the ADA or other federal anti-
discrimination statutes. State anti-discrimination statutes might provide 
greater, but still spotty, protection. 
  
III. THE MORAL CHOICE MODEL MUST BE REPLACED WITH THE IDM 
 
A.  The Competing Causal Models of Addiction 
 
 A well-accepted view of SUD is that it unfolds as a three-step 
process. First comes the binge or intoxication episodes. After enough of 
these episodes, some individuals will become addicted (either through weak 
character, as some posit, or through genetic vulnerability to physical 
dependence, as I suggest). Once the drug is metabolized there is a hang-
over, which leads to negative affect and withdrawal symptoms. This in turn 
leads to the third step of preoccupation, where desire for the drug intensifies 
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and prompts the next intoxication episode.142 This three-step process 
describes the cycle of drug use, whether you think of this process in terms 
of a learning, memory, developmental, reward, impulse, or chemical or 
neuroinflammatory disorder. Stressful life events can lead to continued drug 
use to self-medicate and escape the stress or pain.143 
 How we conceive of addiction impacts our response.144 Some have 
argued that “whether addiction is a disease is much ado about nothing, since 
all parties agree it is ‘unquestionably destructive.’”145 But it does matter. 
While our current moral agency model discourages investments in treatment 
and encourages investment in criminalization, a model that is on equal 
footing with lung cancer or diabetes permits greater research funding and 
insurance parity. So how do we get there? We first need to dig a little 
deeper into the various models.  
 There are as many models of addiction as there are drugs to abuse. It 
makes sense then, that our policy response to addiction has been 
inconsistent and fractured. Scholars have argued that the best way of 
conceptualizing addiction is to see it as either a disorder of development, 
trauma, risk-taking, choice, associative reward learning, memory, opponent 
biological processes, genetics, or neuroscience. Unfortunately, many see 
these as dichotomous and competing, as opposed to complementary.146 
Most scholars keen on identifying the “correct” model of addiction fall in 
the mutually exclusive “brain disease” or “moral choice” camps, even 
though there are many other models.147 Philosophers and legal scholars 
have spilled much ink on this “oftentimes heated scholarly debate” as to 
whether we ought to think of addiction as a moral choice or a disease.148  
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 Though most neuroscientists, leading addiction researchers, and 
even government entities promote addiction as a chronic brain disease149, a 
recent review shows “varied adoption of the brain disease model among 
addiction treatment providers, with some viewing addiction as a purely 
behavioral problem or maladaptive coping mechanism.”150 The disease 
model is typically associated with being less moralized, as the emphasis is 
not on the moral character of the individual, but rather on biological risk 
factors, and a brain that becomes compelled to use drugs.151 The choice 
model invites greater ascriptions of stigma, blame and personal 
responsibility for choosing hedonism over abstinence.152 The moral choice 
model is the one we see most often in our history and popular culture. It has 
done great violence to the treatment of addiction, both individually and as a 
public health crisis.  
B.  The Moral Choice Model of Addiction 
 
 Those advocating the “choice model” emphasize that people can 
and do stop using drugs, with sufficient incentives.153 Some (though not 
many) people with SUD achieve recovery without any medical treatment, 
and they may have never identified with being “sick” or now “cured.”154 To 
this camp, addiction is a failure to exercise agency or self-control, as well as 
a failure to “live up to the standards of a good life.”155 Some of the moral 
choice theorists posit that personal shame is a necessary condition for 
addiction, but that shame need not result in a “moralized” view of 
addiction.156 This interpretation strains credulity. The examples they 
provide, of people feeling ashamed of things that are outside their control, 
such as body deformities, are likely holdovers from shame that was directed 
at people thought to carry infection. To continue this sort of blameless 
shame, or suggest that addiction relies upon it, is to continue this sort of 
irrational holdover.    
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 Proponents of the choice model argue that aspects of drug-taking 
require voluntary action, such as driving to meet a dealer, or leaving work 
early to shoot-up.157 Further, the pleasure that may be derived from 
satisfying a drug craving is understood by some as a rational expression of 
individual preference.158 And rather than seeing the brain changes that can 
be visualized in people with SUD as evidence of a brain disease, they argue 
that the very nature of the brain is to change. Thus, brain changes are not 
equivalent to disease.159  
 While the choice model is the one that most readily lends itself to an 
account that blames the addict and finds them morally responsible, there are 
aspects of the choice model that proponents argue may benefit individuals 
with SUD. For example, envisioning addiction as a brain disease might take 
too much pressure off society to prevent its social determinants, such as 
housing, unstable home lives, personal safety, and employment.160 Further, 
deterministic thinking might lead people with SUD to give-up efforts at 
sobriety if the disease is “fixed” in their brains. Of course, this characterizes 
just one way that the disease model can be operationalized, and assumes 
that there is insufficient funding to address treatment and the public health 
aspects of addiction.161  
C.  The Brain Disease Model of Addiction 
 In contrast to the choice model, the disease model of addiction 
conceptualizes it as a “severe, chronic stage of substance-abuse disorder, in 
which there is substantial loss of self-control, as indicated by compulsive 
drug-taking despite the desire to stop taking the drug.”162 The definition 
from the National Institute on Drug Abuse (NIDA) goes further to state that 
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Providers’ Views About the Disease Model of Addiction and Its Impact on Clinical Practice: a 
systematic review, 37 DRUG AND ALCOHOL REVIEW 697, 697 (2018) 
161 While the federal Opioid Crisis Response Act of 2018 allocated funds to research and treatment, 
some argue it did not go far enough. See, German Lopez, Congress is on the verge of a bipartisan 
opioid package. But experts have big concerns, Vox, Sept. 12, 2018, available online at 
https://www.vox.com/policy-and-politics/2018/9/12/17847358/senate-opioid-crisis-response-act. 
Additional sources of funding are being made available by the Centers for Disease Control, National 
Institutes of Health, and state agencies. See, N.J. Stat. Ann. § 24:6J-6 (West); see also Cal. Health & 
Safety Code § 1179.80 (West); See also Lexy Gross, The Opioid Epidemic and Rural America: Why 
the USDA Should Lead the Response, 10 KY. J. EQUINE, AGRIC. & NAT. RESOURCES L. 257, 277 
(2018) 
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ENG. J. MED. 363, 364 (2016) 
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addiction “is considered a brain disease because drugs change the brain—
they change its structure and how it works. These brain changes can be 
long-lasting, and can lead to the harmful behaviors seen in people who use 
drugs.”163 While addiction no doubt changes the brain, the IDM I advocate 
goes further than merely demonstrating brain changes through functional or 
structural brain imaging. Rather, the IDM recognizes that neurobiological 
vulnerabilities can lead to addiction, as opposed to just flow from it. It 
further situates the brain inside a human being, which has been exposed to 
various environmental stressors and responds differently to drug use. Given 
the potential nuance that a disease model such as the IDM provides, it is 
perplexing that scholars fail to see how it can accommodate and respond to 
its critics.   
 Nonetheless, the brain disease model of addiction remains 
controversial.164 I have given a great deal of thought as to why this might be 
so. I believe proponents of the brain disease model have unnecessarily over-
played their hand, and painted addiction in neuro-essentialist and 
deterministic ways.165 Using metaphors like the “hijacking” of the brain, 
some suggest that the compulsion to use drugs is so great that you might not 
be legally responsible for criminal acts stemming from your addictive 
behaviors. But the latter does not flow from the former, because the brain is 
never completely hijacked.  
 Put simply, some advocates for the brain disease model have fallen 
into the same trap the moral choice camp has fallen in to, which is to think 
that free will and biological causes are mutually exclusive. Addiction is 
either a disease of the brain or it is a voluntary, moral choice. One or the 
other. Black and white. However, to say that addiction is a brain disease is 
not to say that the affected individual loses all capacity to make reasons-
based decisions. Even Owen Flanagan, who argues that addiction is a 
failure of agency, recognizes that the dichotomy between morality and 
biology is false.166 There are aspects of addiction that suggest the person is 
making some constrained choice, and there are aspects of addiction that 
                                                
163 National Institute on Drug Abuse, National Institutes of Health, Drugs, Brains and Behavior: the 
science of addiction, available online at www.drugabuse.gov/publications/drugs-brains-behavior-
science-addiction/drug-abuse-addiction, at p. 2.  
164 Nora Volkow and George Koob, Brain Disease Model of Addiction, why is it so controversial? 2 
LANCET PSYCHIATRY 677, 677 (2015) 
165 Daniel Buchman, Wayne Skinner, and Judy Illes, Negotiating the Relationship Between 
Addiction, Ethics, and Brain Science, 1 AJOB Neuroscience 36, 36 (2010) (“Although a brain 
disease model legitimizes addiction as a medical condition, it promotes neuro-essentialist thinking, 
categorical ideas of responsibility and free choice, and undermines the complexity involved in its 
emergence.”) 
166 Owen Flanagan, The Shame of Addiction, 4 FRONTIERS IN PSYCHIATRY 120 (2013) 
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follow a brain disease model.167 “Endorsing a [disease model of addiction]” 
is not “inconsistent” with a free-will model.168  
 Conversely, even if there is a voluntary choice involved in the 
decision to use drugs for the first, second, or third times, once someone has 
developed SUD, all of their “choices,” including those unrelated to drug 
use, do become significantly constrained, if not perfectly determined.169 The 
volitional nature of behavior is more pronounced in the initiation phase of 
disease, but brain adaptations can reduce volition leading to habits, altered 
reward processing, stress reactivity, and negative affect and physiology of 
withdrawal.170 More will be said about this infra at [x]. 
 
D.  Neither Purely a Brain Disease nor Purely a Moral Choice: 
the IDM 
 
 In adopting the IDM, we need not rely on the “fundamental psycho-
legal error.” The disease model does not suggest that addiction is caused 
only, or even predominantly, by the brain. What’s more, this Article is 
about moral justifications for treatment, not moral justifications for 
punishment. While our models of addiction impact our criminal laws, it is 
not an inevitable step from a disease model to an argument that would 
necessarily be relevant to the criminal law.171 Neuro-genetic factors are but 
one of many relevant types of causes. A disease model would hopefully 
encourage compassion in how we prosecute drug possession, just as a 
history of child abuse or other psychiatric disorders might engender mercy. 
But that does not mean that the individual could never be legally 
responsible for his actions. Indeed, with increased access to effective and 
                                                
167 Rather than being a disease or a choice, addiction might be the result of psychological or 
neurological mechanisms that diminish reasons-responsiveness, due to associative learning. For 
example, according to Marc Lewis, addiction is a “habit that grows and self-perpetuates relatively 
quickly, when we repeatedly pursue the same highly attractive goal. Or, in a phrase, motivated 
repetition that gives rise to deep learning.” Marc Lewis, THE BIOLOGY OF DESIRE: WHY ADDICTION IS 
NOT A DISEASE, New York: Public Affairs, at p. 174 (2015) 
168 Anthony Barnett, et al., Drug and Alcohol Treatment Providers’ Views About the Disease Model 
of Addiction and Its Impact on Clinical Practice: a systematic review, 37 DRUG AND ALCOHOL 
REVIEW 697, 717 (2018)  
169  “Observers will continue to rate the addict as culpable long after the drug is ingested for ‘personal 
choice’ and functional dysregulation and structural alterations have materialized in brain areas that 
regulate motivation and self-regulation in the face of escalating consequences.” G.F., Koob, and M. 
Le Moal. What is addiction, NEUROBIOLOGY OF ADDICTION. Koob  and Le Moal (eds), 
Elsevier/Academic Press, Amsterdam/Boston (2006): 1-22. 
170 Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating 
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *7 (2016) 
171 “[D]iscovery of genetic or of any other physical or psychosocial cause of action raises no new 
issues concerning responsibility, and discovery of such causes does not per se create an excusing or 
mitigating condition for criminal conduct or any other type of behavior.” Stephen J. Morse, 
Addiction, Genetics, and Criminal Responsibility, LAW & CONTEMP. PROBS., Winter/Spring 2006, at 
165, 166. 
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cheaper SUD treatments in the future, prosecutors might have greater moral 
justification for prosecuting people who do not seek it.  
   
 Finally, adopting the IDM does not require that the individual with 
SUD be capable of being “cured.” There are many diseases for which a cure 
is never likely, and the best that can be hoped for is remission or sustained 
recovery.172 And treating addiction as a disease does not mean that we 
should ignore the social determinants of health, such as high-stress 
environments,173 just as we should not ignore the social determinants of 
lung cancer, diabetes, depression or AIDS. Many of the criticisms of the 
brain disease model rely on misunderstandings of the complex etiology of 
‘disease,’ and bring to bear a very constrained model of what it means for 
something to be a choice, as well as what it means for something to be a 
disease. The two are not wholly incompatible. What can be said, 
uncontroversially, is that whether one adopts a disease model, a choice 
model, or something else, that the mechanisms involved in addiction are 
neurobiological. The three phases of addiction are craving, binging, and 
withdrawal, and the resulting physical dependence can be understood and 
explained by neurobiological mechanisms. Further, the process from drug 
use to mild SUD, to moderate SUD, and then to severe SUD, otherwise 
labeled full-blown addiction, can be explained by neurobiological 
systems.174  
 
E.  The Neurobiology of Addiction Does Not Support the Moral 
Choice Model 
 
1. The Brain is Not Hijacked, but Is Constrained in Patients with SUD 
 
 The neurological processes behind the development of addiction 
have been extensively studied. There are different ways to explain what is 
happening at both the neurological and psychological levels. I will offer a 
few of those explanations here, all of which fit neatly within the IDM. It is 
well accepted that drugs activate reward regions in the brain by causing 
sharp increases in the release of dopamine, which sets off a cascade of 
                                                
172 Examples include lung cancer, anorexia nervosa, and substance use disorder.  
173 Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating 
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *6 (2016) 
174 Substance use disorder (SUD) is a diagnostic term used in the DSM-5 referring to recurrent use of 
alcohol or other drugs that cause clinically and functionally significant impairment. This disorder can 
be classified as mild, moderate, or severe. Addiction is used to indicate the most severe stage of this 
SUD process, in which individuals have a substantial loss of self-control, and will use the drug 
despite the desire to stop, and in the face of negative consequences. See, Nora Volkow, et al., 
Neurobiologic Advances From the Brain Disease Model of Addiction, 374 NEW ENG. J. MED. 363, 
364 (2016).  
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reinforcement learning and Pavlovian conditioning.175 As with any other 
form of motivated learning, the greater the associated reward, the more 
work someone is willing to do to get it.176 When it comes to “natural 
reward,” dopamine cells reduce their firing in response to food or sex, once 
someone is considered sated. This is not the case with drugs, which can 
circumvent the satiation mechanisms of the brain.177 However, this effect 
tapers off. With repeated use, dopamine cells cease firing in response to the 
drug itself, and instead fire in anticipation of the conditioned stimuli, or 
drug cue.178  
 Another complementary way of explaining drug use is in terms of 
“opponent process” theory. Under this explanatory model, once the positive 
euphoric state is triggered (the a-process), brain mechanisms will work to 
reduce the intensity of this affective state (the b-process). The intoxication 
phase, or the “a-process,” motivates the individual to seek more of that 
pleasurable stimuli—in this case drugs.179 The a-process does this by 
triggering dopamine and opiate peptides to bind to receptors in the VTA 
and nucleus accumbens, which mirrors the reinforcement learning 
process.180  
 After the effects of an opioid wear off, the b-process begins. This b-
process produces sharp declines in dopamine and opioid peptide neurons, 
and increases stress steroids such as adrenaline and corticotropin-releasing 
factor (CRF). While these operate to return an individual to baseline, in 
someone with SUD, the b-process fuels the addiction, by generating 
physical dependence and withdrawal at the synaptic level. The sharp 
increase in CRF and adrenaline, coupled with the desensitization of 
dopaminergic receptors and the release of dynorphin, leads to mood 
irritability, emotional pain, malaise, dysphoria, alexithymia, and as 
discussed above, increases the threshold for experiencing reward.181 The 
pathway between the paraventricular nucleus of the thalamus (PVT) and the 
nucleus accumbens has been identified as a prominent neural circuit in 
                                                
175 Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374 
NEW ENG. J. MED. 363, 364 (2016). 
176 Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374 
NEW ENG. J. MED. 363, 366 (2016). 
177 Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374 
NEW ENG. J. MED. 363, 366 (2016). 
178 Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374 
NEW ENG. J. MED. 363, 364 (2016). 
179 George Koob and Michel Le Moal, Neurobiological mechanisms for opponent motivational 
processes in addiction, 363 PHIL. TRANSACT. OF THE ROYAL SOCIETY 3113, 3114 (2008). 
180 George Koob and Michel Le Moal, Neurobiological mechanisms for opponent motivational 
processes in addiction, 363 PHIL. TRANSACT. OF THE ROYAL SOCIETY 3113, 3120 (2008). 
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relaying aversion and memory of withdrawal symptoms.182 Amazing new 
research, silencing this pathway through optogenetics, suppressed 
physiological withdrawal and aversion in the drug dependent state.183 This 
sort of methodology, that can demonstrate cause and effect by disrupting 
the neural circuitry of the “addicted brain,” is promising, but in need of 
replication. 
 Repeated exposure to dopamine-triggering drugs leads to adaptions 
in the circuitry of the brain, most notably in the striatum, ventral tegmental 
area, (VTA) and basal forebrain.184 Eventually the intensity of this a-
process euphoria levels off in response.  We can see this as each time the 
same drug is used, the release of dopamine is diminished in the synapses.185 
This explains why people with addiction “chase the dragon,” and no longer 
experience the same euphoria they first experienced when using the drug. 
This eventual attenuation makes the brain’s reward system much less 
sensitive to stimulation of rewards of all types—including drugs but also 
food, relationships, and activities.186 The neuroscientific changes are 
engrained in the brain and take a long time to reverse.187  It is because of 
this altered neurobiology that the analogy of addiction to lung cancer or 
diabetes stops being helpful, however. Addiction is different. The disease 
itself can lead you to sabotage your own recovery, by creating a 
physiological pull to use drugs, despite strong personal desires to quit. It 
would be as if lung addiction had a symptom that made you averse to 
chemotherapy or surgery. Once someone develops the disorder of addiction, 
the motivation to use drugs can eclipse the motivation to eat or sleep. 
Avoiding withdrawal might become the chief motivating factor in one’s 
life.   
 The brains of people with severe SUD have adapted to expectations 
of sustained, high volume drug use, and at the same time their receptors are 
increasingly insensitive to the dopamine that is being produced. This helps 
                                                
182 Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating 
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *7 (2016)  
183 Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating 
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *7 (2016)  
184 JOSHUA JENNINGS, ET AL., DISTINCT EXTENDED AMYGDALA CIRCUITS FOR DIVERGENT MOTIVATIONAL 
STATES, 496 Nature 224, 224 (2013)  
185 “[D]rug consumption triggers much smaller increases in dopamine levels in the presence of 
addiction (in both animals and humans) than in its absence (i.e., persons who have never used drugs.” 
See, Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374 
NEW ENG. J. MED. 363, 366 (2016). 
186 “[D]rug consumption triggers much smaller increases in dopamine levels in the presence of 
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to explain the observed behavior of people with addiction. Neural circuit 
adaptations make individuals more reactive to stress.188 This in turn leads to 
greater vulnerability to depression and anxiety, which in turn can lead to 
greater drug use as a form of “self-medication” to ease the anxiety.189 Many 
say that they really want to stop using, but get caught in the vicious cycle of 
administering drugs to escape the anxiety and physical distress that is 
produced by their vulnerable neuro-circuitry, and physical withdrawal. And 
at the same time, what used to be an impulsive, or voluntary, choice to use 
drugs has now become much more compelled.  
 
 Trevor Robbins’ lab at Cambridge has studied this shift in 
neurobiology when people go from impulsive to compulsive drug use.190 He 
posits that individuals first associate the drug with either euphoria or just 
relief from aversive conditions.191 Then, when drug use is escalated, in 
vulnerable individuals it leads to dependence. More will be said about what 
makes individuals vulnerable, infra, at [x]. The third step to addiction, or 
severe SUD, comes when reward circuitry is changed, leading to insensitive 
sensitization and a strong motivation for drug use.192 Specifically, Robbins’ 
research describes: 
 
“evidence that the switch from controlled to compulsive drug 
seeking represents a transition at the neural level from prefrontal 
cortical to striatal control over drug-seeking and drug-taking 
behaviours as well as a progression from ventral to more dorsal 
domains of the striatum, mediated by its serially interconnecting 
dopaminergic circuitry. These neural transitions depend upon the 
neuroplasticity induced by chronic self-administration of drugs in 
both cortical and striatal structures, including long-lasting changes 
that are the consequence of toxic drug effects.”193  
 
                                                
188 George Koob and Michel Le Moal, Neurobiological mechanisms for opponent motivational 
processes in addiction, 363 PHIL. TRANSACT. OF THE ROYAL SOCIETY 3113, 3114 (2008). 
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 There is a substantial literature documenting reduced white matter 
and damaged myelin in the brains of people with OUD,194 as well as deficits 
in blood-oxygenated level responses (BOLD) evidenced on functional 
magnetic resonance imaging. People with SUD have “showed less 
activation in the frontal lobe than healthy subjects during the cocaine cue 
tapes, suggesting that their ability to control their cue responses was 
inhibited.”195  In a different study, researchers found that chronic cocaine 
abusers had abnormally low levels of activity in midline areas of the 
anterior cingulate that are crucial for cognitive and behavioral control.196 
 
 More recent and sophisticated methods have documented impaired 
expression of genes related to the formation of blood cells and Tumor 
Necrosis Factor (TNFα) signaling in the peripheral blood of individuals 
with OUD.197 Tumor Necrosis Factor is an inflammatory cytokine that been 
considered as an anti-cancer agent. Reduced expression suggests reduced 
immune function in people with OUD. These researchers also found up-
regulation of mitochondrial genes and splicing related genes, which are 
critical for generating different functional transcripts of the same gene.198 
These are biomarkers of physical dependence on heroin, and the biomarkers 
overlap with impairment seen in people with other neurodegenerative 
disorders.199 
  
 While none of what I outlined above is controversial, some still 
argue that addiction is not a biological or brain disease. The main reasons 
given are 1) that the first decisions to use drugs are largely voluntary, and 2) 
not everyone who uses drugs will ultimately become addicted. However, 
this fails to recognize the importance of biological and environmental risk 
factors in disease. Just as many people smoke who do not develop lung 
cancer, or many people eat too many carbohydrates do not develop diabetes, 
not everyone who uses drugs will develop physical dependence and 
addiction. The differing results can be explained in part by our unique 
genetic predisposition to SUD. 
                                                
194 Mei Zhu, et al., Heroin Abuse Results in Shifted RNA Expression to Neurodegenerative Diseases 
and Attenuation of TNF gamma Signaling Pathway, 8 SCIENTIFIC REPORTS 1, 5 (2018) 
195 JOANNA FOWLER, ET AL., IMAGING THE ADDICTED HUMAN BRAIN, 3 Sci. Pract. Perspect. 4-16 (2007) 
196 JOANNA FOWLER, ET AL., IMAGING THE ADDICTED HUMAN BRAIN, 3 Sci. Pract. Perspect. 4-16 (2007) 
197 See, ThermoFisher Scientific, TNF Signaling Pathway, available online 
https://www.thermofisher.com/us/en/home/life-science/antibodies/antibodies-learning-
center/antibodies-resource-library/cell-signaling-pathways/tnf-signaling-pathway.html 
198 Mei Zhu, et al., Heroin Abuse Results in Shifted RNA Expression to Neurodegenerative Diseases 
and Attenuation of TNF gamma Signaling Pathway, 8 SCIENTIFIC REPORTS 1, 8 (2018) This analysis 
was conducted by comparing the RNA-seq data with healthy controls and people with OUD. 
199 Mei Zhu, et al., Heroin Abuse Results in Shifted RNA Expression to Neurodegenerative Diseases 
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2. It is Not Just that Addiction Changes the Brain, Our Brains Can 
Predispose Us to Addiction   
  
 There is no magic dose or duration of opioid use that will 
predictably result in SUD. This is because not everyone is born with the 
same neuro-genetic risk factors, and not everyone experiences the same 
levels of childhood trauma or stress. Addiction has both genetic and 
environmental influences, similar to many other complex and chronic 
diseases.200 The genetic contribution to SUD is substantial, and accounts for 
somewhere between 40 and 50% of the risk associated with addiction.201 
Clinical studies have shown that the heritability rates of opioid addiction are 
“similar to those of diabetes, asthma, and hypertension.”202 Additionally, 
because of the “enhanced neuroplasticity of their brains and their 
underdeveloped frontal cortex, which is necessary for self-control,” 
adolescents are at an increased risk of developing SUD.203 
 There are many ways we can learn about the genetic contributions to 
traits. A conventional method looks to family and twin epidemiological 
studies, where we expect to see higher rates of addiction in homozygotic 
twins than in heterozygous twins, and more in both than we see in siblings. 
These studies show heritability estimates ranging from 30-60%.204 The 
variation is large because some genetic variants are common to all 
addictions and some affect risk to only a particular drug. 205 For example, 
while twin studies show that SUD risk is shared among multiple classes of 
drugs, some genetic risk is specific to a class of drugs, such as opiates. 206 
Further, each stage of SUD will be impacted differently by genetics and the 
environment. The transitions from initiation of drug use to routine drug use, 
to physical dependence and even relapse may be driven by different genetic 
factors, as they involve different physiological processes. 207  
                                                
200 Kenneth Blum, et al., Genetic Addiction Risk Score (GARS), a predictor of vulnerability to opioid 
dependence, 10 FRONT. IN BIOSCIENCES 175, 177 (2018).  
201 Nora D. Volkow and A. Thomas McLellan, Opioid Abuse in Chronic Pain — Misconceptions and 
Mitigation Strategies 374 NEW ENGL. J. MED. 1253, 1257 (2016); Volkow & Boyle, 175 Am. J. 
Psychiat. 729 (2018) “Genetic Factors Account for Roughly 50% of the Risk of Addiction.” 
202 Nora D. Volkow and A. Thomas McLellan, Opioid Abuse in Chronic Pain — Misconceptions and 
Mitigation Strategies 374 NEW ENGL. J. MED. 1253, 1257 (2016) 
203 Nora D. Volkow and A. Thomas McLellan, Opioid Abuse in Chronic Pain — Misconceptions and 
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204 Mary Jeanne Kreek et al., Genetic influences on impulsivity, risk taking, stress responsivity and 
vulnerability to drug abuse and addiction, 8 NATURE NEUROSCIENCE 1450, 1450 (2005) 
205 Mary Jeanne Kreek et al., Genetic influences on impulsivity, risk taking, stress responsivity and 
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 In addition to twin studies, researchers are using several novel 
techniques to discover the patchwork of genes involved in addiction 
generally, and OUD in particular. In the early 1970s, there was a “game-
changing” discovery that opiate drugs bind to receptors in the brain, 
commandeering the endogenous internal system for reducing pain. There 
are three G protein-coupled receptors (GPCRs) in the opioid system, known 
as mu-, delta- and kappa-opioid receptors (MORs, DORs and KORs, 
respectively). Under normal conditions, these receptors are stimulated by 
endogenous opioid peptides, such as β-endorphin, enkephalins and 
dynorphins, that may be triggered in response to physical exertion or pain. 
However, when someone takes illicit drugs like heroin or pain medications 
like hydrocodone, these drugs easily bind to the same mu-opioid receptors, 
triggering a cascade of pain relief, pleasure, and dependence. 
 Recent research into the varying roles of the opioid receptors have 
yielded new insights into their crucial roles in regulating the opponent-
processes of pain and pain relief.  Opioid receptors play a role in each of the 
three steps of SUD. Activation of the MOR during intoxication triggers 
pleasure, or what was referred to as the a-process. Repeated MOR 
activation leads to reduced drug reward (tolerance) and dependence or 
withdrawal symptoms. KORs trigger the b-process of dysphoria through 
dynorphin, which characterizes withdrawal and abstinence. 208 Stress and 
drug abuse both enhance KOR–dynorphin signaling209. The DOR regulates 
reinforcement learning and memory, while also reducing anxiety and 
depressive states. 210 In the relapse stage, evidence supports a role for DORs 
in context learning and memory for drug cues, like drug paraphernalia or 
drug-using friends.211 All three opioid receptors likely influence the 
preoccupation and craving state, and are implicated in drug-biased 
motivation, habit formation and loss of inhibitory control. 212 Support for 
these roles comes from locations in the mouse brain with high receptor 
density, but these aspects are less well-characterized in the human brain.213  
                                                                                                                       
 
208 Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the Onset, 
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 Given these unique receptor properties, targeting specific opioid 
receptors, by blocking KOR and activating DOR, is a promising target for 
the treatment of addiction, and other disorders like depression that stem 
from low reward or high-aversion states. Interestingly, when researchers 
deleted the OPRM1 gene in mice, this “simultaneously eliminated the 
analgesic, rewarding and dependence-inducing effects of morphine, 
demonstrating that the MOR is the sole responsible receptor for both the 
therapeutic and the adverse actions of morphine.”214 Mutations in this 
receptor gene have been repeatedly associated with increased addiction 
risk.215 Recent research suggests there is substantial overlap between the 
genetic correlates of opioid addiction and pain sensitivity,216 with one team 
positing that mutations in the mu-opioid receptors might actually be the 
drivers of not just OUD, but other forms of SUD.217 
 Of course, there are different pathways to addiction. There is no 
“one gene” for addiction risk. Despite the significant role of mutations in 
the opioid receptors, mutations in other genes also contribute to addiction 
risk. Genome-wide association studies (GWAS) have found significant 
associations between mutations linked with potassium and calcium 
signaling networks in the brain, and developing OUD.218 These results were 
most profound in the African-American subgroup sample. 219 Glutamate, an 
excitatory neurotransmitter, also plays a large role in addiction. The N-
methyl-d-aspartate (NMDA) glutamate receptor gene GLUN3A has been 
shown to serve an important role in the development of addiction.220 
                                                                                                                       
amygdala likewise has a high density of MOR, and to a lesser extent, KOR receptors. The MOR 
receptors in the amygdala promote pleasure, while the KOR receptors in the amgydala promote 
anxiety. The hippocampus has a high density of MOR and KOR receptors, and is critical in memory 
formation.  See, Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the 
Onset, Progression, and Maintenance of Addiction, 19 NATURE REVIEWS NEUROSCi 499, 504 (2018) 
214 Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the Onset, 
Progression, and Maintenance of Addiction, 19 NATURE REVIEWS NEUROSCi 499, 499 (2018) 
215 Specifially, mutations on the OPRM1; OPRK1; OPRD1; PDYN; POMC; PENK receptor genes 
have all been associated with increased risk of OUD. See, Kenneth Blum, et al., Genetic Addiction 
Risk Score (GARS), a predictor of vulnerability to opioid dependence, 10 FRONT. IN BIOSCIENCES 
175, 179 (2018). 
216 “The[se] genes involved in the addictive process can also be indicative of which genes are 
engaged in pain mechanisms, pain sensitivity, and opiate addiction.” See, Kenneth Blum, et al., 
Genetic Addiction Risk Score (GARS), a predictor of vulnerability to opioid dependence, 10 FRONT. 
IN BIOSCIENCES 175, 179 (2018) 
217 Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the Onset, 
Progression, and Maintenance of Addiction, 19 NATURE REVIEWS NEUROSCi 499, 499 (2018) 
218 Joel Gelernter, et al., Genome-Wide Association Study of Opioid Dependence: Multiple 
Associations Mapped to Calcium and Potassium Pathways, 76 BIOL. PSYCH. 66, 66 (2014) 
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Mutations on the GABA receptors have also been implicated, through 
microarray, single-gene strategies, and genome-wide association studies.221  
 
 Due to the heavy involvement of dopaminergic pathways, mutations 
on the dopamine receptor gene, D2, (located on chromosome 11 q22-q23) 
have been extensively studied.222 Hundreds of studies have connected the 
DRD2 gene in particular  to OUD, suggesting low baseline levels of 
hedonia and higher levels of anxiety as the behavioral phenotypes that give 
rise to abuse.223 One lab has determined that the DRD2 A1 mutation has a 
Positive Predictive Value (PPV) of 74%, indicating “that if a child is born 
with this polymorphism they have a very high risk of becoming addicted to 
either drugs, food, or aberrant behaviors at some point in their future.”224 
 
 In addition to the substantial and growing evidence of genetic 
contributions to SUD, there is extensive research on the genetic risk for 
behavioral endophenotypes of addiction. For example, traits such as 
impulsivity, risk-taking and depression may contribute to the initiation of 
drug use as well as the transitions from initial use to regular use to 
addiction. As Robbins’ team has documented, individuals with hypo-
dominergic systems (reduced endogenous dopamine release) and impaired 
inhibitory control in the cerebral cortex are vulnerable to developing 
SUD.225 Impulsive rats are not only much more likely to escalate self-
administration of cocaine but also much more likely to relapse to a drug-
seeking habit after some period of abstinence.226 People with depression227 
and anxiety are also at increased risk of SUD. Each of these personality 
dimensions, or endophenotypes, has its own complex genetic basis.228 
 Given that a significant risk factor for developing addiction lies in 
our genes, one lab has gone so far as to create a Genetic addiction risk score 
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dependence, 10 FRONT. IN BIOSCIENCES 175, 177 (2018). 
223 Kenneth Blum, et al., Genetic Addiction Risk Score (GARS), a predictor of vulnerability to opioid 
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(GARS).TM229 It is hoped that these risk scores, calculated based on the 
presence of multiple mutations, can better predict the development of SUD, 
and relapse. These tools may one day be used in the clinic, as a screening 
tool for prescribing addictive medications like opioids, or to help prevent 
problem drug-use before it rises to the level of dependence.  
 
3. Genetic Explanations Might Reduce Responsibility, But Do Not Reduce 
Stigma on Their Own 
 
 We now know that addiction is caused in large part by our genes, 
which we have no control over and we cannot change. Given this, some 
have suggested that, “questions about right or wrong-doing seem to be ill-
posed.”230 This is because we typically blame people for things that are 
under their control, and for which they make a voluntary decision to do.231 
It is much harder to justify blaming someone for their behavior, once we 
know that for genetic reasons, it is considerably more difficult for them to 
conform their behavior to a particular standard. This presents some 
challenges to the pure moral choice model of addiction, as there are clear 
inequities in our inherent abilities to refrain from becoming dependent.  
 Do we blame people for developing PTSD or Alzheimer’s? And 
even if we continue to blame someone for developing lung cancer or 
diabetes, because these too are caused in part by behavioral choices, we still 
view these diseases as a medical problem deserving of a medical treatment. 
It would be far too ambitious to expect the IDM to erase stigma completely. 
Rather, the IDM model will be more effective at helping policymakers and 
the public understand that some people are much more vulnerable to 
addiction, due to their neuro-genetics. This would hopefully lead to policies 
that emphasize treatment, prevention, and harm-reduction, rather than 
criminalization and social isolation. Addiction is a disease, we should treat 
it like one. While we can and must address social and personal 
determinants, we must initially focus primarily on the primary determinants 
of health, as we would with any other disease. 
 Proponents of the brain disease model have argued that a 
neuroscience perspective reduces attributions of free will, (namely volition 
                                                
229 See, Kenneth Blum, et al., Genetic Addiction Risk Score (GARS), a predictor of vulnerability 
to opioid dependence, 10 FRONT. IN BIOSCIENCES 175, 179 (2018). 
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Modest Impact on the Attribution of Free Will to People With an Addiction, 8 FRONTIERS IN PSYCHOL. 
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and responsibility) because it “relocates the disorder to the brain, rather than 
to the person.”232 However, as mentioned infra at [x], the disease need not 
be “located” in the brain to be an ordinary disease worthy of treatment. In 
keeping with this general idea, the National Alliance on Mental Illness 
(NAMI) argued that once the public understood mental illnesses to be a 
“real,” disease, and with a similar biological etiology to cancer or diabetes, 
prejudice and discrimination would fade.233 Their campaign, “A Disease 
Like Any Other,” focused on educating people about the brain disease 
model of mental illnesses such as addiction.  National surveys have 
documented the success of their educational messaging, with mental health 
literacy increasing significantly in recent decades.234 Many more Americans 
now appreciate that substance abuse has a large hereditary and 
environmental component, and is not entirely a disease of the weak-
willed.235   
 However, importantly, so far this has not lead to universal, reduced 
attributions of stigma.236 Indeed, attributing addiction to genetic factors, 
may have caused some backlash.237 This may be because genetic causes 
appear immutable and with lasting impact for generations.238  
 Two meta-analyses, looking at the effect of the brain disease model 
on attributions of responsibility and stigma yielded consistent patterns. 
When the team reviewed the experimental studies, they indicated that 
neuro-genetic explanations “reduced blame, increased perceived 
dangerousness and prognostic pessimism, and had no effect on social 
distance.”239 Their review of the correlational studies found that “people 
who endorse biogenetic explanations tend to blame affected persons less for 
their problems, but perceive them as more dangerous and desire greater 
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social distance from them.”240 No correlational studies addressed prognostic 
pessimism. These findings led the researchers to propose the “mixed 
blessings” model of stigma. Fueled in part by a belief that a “deep seated, 
hidden essence is shared by all members of a category” the brain disease 
model reduced individual control and therefore moral responsibility, but 
increased  genetic essentialist thinking, or that affected people have 
predictable traits that can be explained almost entirely by their genes. 241 
Essentialist thinking leads to fear, social distance, and pessimism about 
treatment, as the genes are given a powerful role in determining behavior.242 
When we think of people as having a difference, that is immutable, can be 
labeled, and that leads to antisocial behavior, this can engender the very 
stigma and dehumanization we sought to avoid.243  
 In contrast, people may think of neurobiological causes of disorders 
as less binary than genetic causes, as brains are less static, and more plastic. 
Genes may be thought of as deep, ultimate causes, with the brain operating 
at a more intermediate level of translation244. A study focusing more on the 
neuroscientific explanations of mental illness generally, found similar 
results to the genetic studies.245 However, as an author of one of the studies 
included in the analysis, the authors could not conclude that our study 
isolated neuroscientific explanations, as our causal model included genetics 
and neuroscience explanations for the aberrant behavior.246 Nonetheless, the 
authors concluded that it could be that people misunderstand how the brain 
works and think of it deterministically like genes. Or, it could be that 
understanding someone as having reduced behavioral control makes them 
more unpredictable, and therefore, scarier and deserving of punishment.  
 A recent experiment sought to explore the impact of neuro-genetic 
causal models of addiction on attributions of free will and responsibility. 
The researchers showed respondents text and a neuro-image (which 
unfortunately explained the neurobiological basis of addiction by 
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referencing reduced dopamine receptors in people who have SUD, which 
could be an effect of the disorder rather than a cause), and compared this 
with a control group. The respondents were asked to indicate the extent to 
which they agreed with statements about cocaine addicts’ and alcoholics’ 
diminished free will.247 The findings were modest, but found attributions of 
volition were somewhat reduced for the cocaine subsample, when 
respondents viewed the textual and neuro-image explanations together, but 
there was no effect when respondents viewed the text or neuro-image alone, 
or when the information applied to alcoholics.248 However, respondent 
characteristics such as education and self-reported knowledge of 
neuroscience were associated with lower attributions of responsibility for 
both substances, and education was associated with lower attribution of 
volition for the alcohol sub-sample.249  
 In summary, the brain disease model has not been an unmitigated 
success. There are risks associated with explaining addiction in terms of 
neuroscience, as “descriptive neuroscience concepts are inseparable from 
historical attitudes and intuitions towards addiction and addicted persons. 
Placing emphasis on the diseased brain may foster unintended harm by 
paradoxically increasing social distance towards the vulnerable group the 
term is intended to benefit.”250 However, it has moved the needle on 
pushing the public to support more treatment. While endorsements of a 
genetic cause of addiction has led to greater support for seeking treatment 
from psychiatrists, hospitals, and medications, in some cases it has also 
provoked greater cynicism about the potential efficacy of treatment.251 
Clearly, the brain disease model of addiction, relying solely on neuro-
genetics, cannot work alone. 
 
F.  We Must Develop a New Public Health Campaign Based on 
the IDM 
 
 The brain disease model of addiction, with a heavy emphasis on the 
idea that the brain is “hijacked” and the genes are determined, has not 
                                                
247 Eric Racine, Sebastian Sattler, and Alice Escande, Free Will and the Brain Disease Model of 
Addiction: The Not So Seductive Allure of Neuroscience and Its Modest Impact on the Attribution of 
Free Will to People With an Addiction, 8 FRONTIERS IN PSYCHOL. 1850, 1850-51 (2017) 
248 Eric Racine, Sebastian Sattler, and Alice Escande, Free Will and the Brain Disease Model of 
Addiction: The Not So Seductive Allure of Neuroscience and Its Modest Impact on the Attribution of 
Free Will to People With an Addiction, 8 FRONTIERS IN PSYCHOL. 1850, 1850-51 (2017) 
249 Eric Racine, Sebastian Sattler, and Alice Escande, Free Will and the Brain Disease Model of 
Addiction: The Not So Seductive Allure of Neuroscience and Its Modest Impact on the Attribution of 
Free Will to People With an Addiction, 8 FRONTIERS IN PSYCHOL. 1850, 1850-51 (2017) 
250 Daniel Buchman, Judy Illes, and Peter Reiner, The Paradox of Addiction Neuroscience, 4  
NEUROETHICS, 65, 66 (2011) 
251 Bernice Pescosolido, The Public Stigma of Mental Illness: What Do We Think; What Do We 
Know; What Can We Prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 11 (2013). 
 Electronic copy available at: https://ssrn.com/abstract=3345176 
1-Mar-19] Addiction as Disease 44 
 
worked so far to reduce stigma and increase treatment. What is needed is a 
more nuanced model, such as the IDM, that can confront the reality of 
addiction as a disease, with neuro-genetic and environmental risk factors 
which exist on a continuum, and for which there are successful treatments. 
Recent data from public health suggests that when combined in this way, 
the neuro-genetic evidence can work to reduce stigma.  Rather than seeing 
the brain as hijacked and controlling the disease process entirely, the IDM 
can explain important causes of addiction as neuro-genetic, while 
recognizing the importance of environmental risk and personal choice. We 
need to stop feeding the false dichotomy of disease or choice, with a more 
nuanced public health campaign that is experimentally tested and uses 
destigmatizing language and images.252  
 
 The false dichotomy has led some physicians to flip back and forth 
between the moral choice and disease model, when explaining addiction to 
their patients.253 Studies demonstrate that physicians feel the need to switch 
back and forth between “their deployment of disease, moral and social 
models depending on how they wish to frame a client’s sense of 
responsibility for the problem and the solution...” 254 Rather than asking 
physicians to be agile, and selectively employ different models of addiction, 
the IDM allows them to speak with one consistent message.255 There are not 
competing models of addiction—there is one model that accommodates 
developments in neuro-genetics and psychology, and reflects the reality of 
people living with addiction, that it involves some level of individual 
choice, and leads to antisocial behaviors that we would like to see treated. 
The only reason this simple resolution has been so hard to grasp in the field 
of addiction, and not elsewhere, is the pervasiveness of the stigma 
surrounding the disease. 
 
a. Part 1 of the Public Health Campaign: Addiction Risk Exists on A 
Continuum, And Presents as a Neurobiological Disease 
 
 So far, the “dialogue around opioids has been dominated by several 
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approaches that on their own are inadequate or harmful.”256 To mitigate 
stigma, we must develop a comprehensive public health campaign that is 
based on a model like the IDM. This campaign should rely on individual 
stories as well as data, to explain the simple facts that anyone—no matter 
their education, class, or race—can develop SUD.257 Using the 
neurobiological evidence for SUD, the public health message must also 
include information that once someone is addicted, their voluntary choices 
are highly constrained because of the disease. The specific messaging of the 
campaign should be created after experimental testing.258 However, recent 
studies from public health make it clear that certain types of messages will 
be more successful than others to reduce stigma and encourage treatment.  
 The first way we can reduce the “othering” of people with addiction 
is to emphasize that the disease, and its risk factors, exist on a continuum. 
While some were concerned that a model of addiction that focused on the 
brain would encourage an “Us vs. Them” dynamic, (the normal and the 
diseased), we can diminish this effect by instead by focusing on the idea 
that risk factors are not categorical, and each of us has varying degrees of 
genetic risk.259 
 People with SUD are not categorically different from us. Rather, 
they have underlying genetic and environmental vulnerabilities, and these 
risks are present to a degree in each of us. With the right combination of 
factors, any one of us can be affected. Addiction is not a disease of the weak 
or immoral. Public health campaigns should emphasize that there is an 
underlying vulnerability in each of us that we did not cause and cannot 
control. As there are different pathways to addiction, some of us are at 
greater risk due to our genes for processing opioids, genes for processing 
dopamine, or genes for memory encoding, etc. If you prefer to speak in 
terms of endophenotypes, some of us are at greater risk due to our anxiety, 
depression, or impulsivity.260 This is consistent with the Research Domain 
Criteria put forward by the National Institutes of Health, which advocates 
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for understanding mental illness as a constellation of component 
psychological and neurobiological processes, which exist on a continuum.  
Each mental illness can be conceived of as a natural process, such as reward 
learning or fear processing, that has become extremely disordered. But we 
all have varying levels of disorder in different domains.  
 This non-categorical way of thinking is in keeping with the new 
Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for SUD, 
which recognizes that SUD exists on a continuum.261 This is not only the 
right way of thinking about SUD, in terms of our underlying neuro-genetic 
risk factors. It will also reduce the extent to which we think of people with 
SUD as the categorical “other,” which can lead to stigma and 
dehumanization.  
 Viewing SUD as existing on a continuum can also help people get 
treatment sooner. It is difficult to remove the stigma from addiction because 
people conflate severe SUD with all forms of SUD.262 People do not get 
treatment because they do not want to accept the label of “addict,” because 
in their minds there is only recreational drug us, and extreme, full-blown 
“addiction.” There is nothing in the middle. Getting people to access 
treatment when the disease is in its modest or early stages will lead to much 
better recovery outcomes. Just as lung cancer patients have much better 
prognoses if the cancer is caught at Stage 2 rather than at Stage 4, so too do 
patients with modest SUD fair better than people with severe SUD.  
 
b. Part 2 of the Public Health Campaign: Addiction is Treatable 
 
 When reporting on addiction, journalists often focus on specific 
individuals, even when the highlighted individual is atypical.263 The public 
then extrapolates from this narrative, which impacts how they view the 
entire affected population.264 Most U.S. news media coverage of opioid 
analgesic abuse from 1998 to 2012 focused on illegal drug dealing and 
over-prescribing of pain medications by physicians.265 Among the news 
stories that mentioned a solution, law enforcement arrests and punishment 
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were mentioned most frequently, at 64% of news stories, with only 3% 
mentioning expanding substance use treatment and less than 1% suggesting 
harm-reduction policies.266 In keeping with the moral choice model of 
addiction, news stories emphasized OUD as a criminal issue, rather than as 
a treatable medical condition.267 This has exacerbated stigma, as people 
think of SUD as an untreatable condition. This may also be why 65% of 
Americans thought people with untreated alcoholism were likely to be 
violent, and 87% thought someone with untreated cocaine dependence were 
likely to be violent, even though they are much more likely to injure 
themselves.268 Stories that depict addicts as dangerous are more likely to 
lead to stigmatized views and a sense that these people need to be punished. 
 Newsflash: most people who are treated for SUD with evidence-
based treatments achieve remission.269 This fact needs to be much more 
widely known. We need to fund public health campaigns that emphasize 
treatment options, and the efficacy of those options.270 A few recent studies 
demonstrate that when news media mentions treatability, this is positively 
correlated with endorsing mental health treatment policies.271 Further, when 
drug addiction is portrayed as a treatable health condition, this reduces 
desire for social distance, improves belief in the effectiveness of treatment, 
and lessens willingness to discriminate against people with SUD.272 
Specifically, as compared to respondents who read vignettes about 
untreated OUD, when respondents read vignettes about individuals with 
SUD who had been successfully treated, this group was much less likely to 
reject the prospect of working with someone with addiction or having them 
marry in to the family.273 Reading about individuals in recovery also made 
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respondents more likely to believe treatment can effectively control 
symptoms, though this particular study did not find support for increased 




 The IDM I propose recognizes that SUD is not a moral failing, but a 
complex and chronic disease, with environmental and neuro-genetic risk 
factors. Rather than furthering the false dichotomy between moral choice 
and biological disease, the IDM places addiction on equal footing with 
other complex and chronic diseases, such as lung cancer or diabetes, each of 
which has environmental and genetic risk factors. Through the IDM, the 
policy and public health emphasis can be properly placed on treatment. 
Given that addiction is a medical problem, our primary response should be 
medical, not criminal—and not even sociological. While we should not 
ignore important social determinants of health, such as childhood trauma, 
access to safe housing and jobs, and criminal justice reform, these should be 
secondary concerns. Addiction is a disease, but due to rampant 
dehumanization of people with addiction, we have failed to see it as such. 
The stigma surrounding people with SUD is rampant, and will take 
concerted effort to mitigate. By engaging in a massive public health 
campaign that emphasizes that addiction risk is neuro-genetic and exists on 
a continuum, that once addiction takes hold voluntary choices related to 
drug use are constrained, and that treatment can be quite effective, we can 
start telling a different, and more hopeful story about recovery.  As stigma 
in its many forms is a major obstacle in the treatment of addiction, 
mitigating stigma will have a cascade of positive effects. Reducing stigma 
will encourage people to seek treatment, will help ensure that the treatment 
that they receive is evidence-based and compassionate, and will reduce the 
unfair discrimination and criminalization that people with SUD experience. 
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